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NOVEL COMPUTATIONAL METHODS 
FOR CANCER GENOMICS DATA ANALYSIS 
 
Cancer is a genetic disease responsible for one in eight deaths worldwide. The 
advancement of next-generation sequencing (NGS) technology has revolutionized the 
cancer research, allowing comprehensively profiling the cancer genome at great resolution. 
Large-scale cancer genomics research has sparked the needs for efficient and accurate 
Bioinformatics methods to analyze the data. The research presented in this dissertation 
focuses on three areas in cancer genomics: cancer somatic mutation detection; cancer 
driver genes identification and transcriptome profiling on single-cell level.  
NGS data analysis involves a series of complicated data transformation that convert 
raw sequencing data to the information that is interpretable by cancer researchers. The first 
project in the dissertation established a robust, reproducible and scalable cancer genomics 
data analysis workflow management system that automates the best practice mutation 
calling pipelines to detect somatic single nucleotide polymorphisms, insertion, deletion and 
copy number variation from NGS data. It integrates mutation annotation, clinically 
actionable therapy prediction and data visualization that streamlines the sequence-to-report 
data transformation.  
In order to differentiate the driver mutations buried among a vast pool of passenger 
mutations from a somatic mutation calling project, we developed MEScan in the second 
project, a novel method that enables genome-scale driver mutations identification based on 
mutual exclusivity test using cancer somatic mutation data. MEScan implements an 
efficient statistical framework to de novo screen mutual exclusive patterns and in the 
meantime taking into account the patient-specific and gene-specific background mutation 
rate and adjusting the heterogenous mutation frequency. It outperforms several existing 
methods based on simulation studies and real-world datasets. Genome-wide screening 
using existing TCGA somatic mutation data discovers novel cancer-specific and pan-
cancer mutually exclusive patterns.  
Bulk RNA sequencing (RNA-Seq) has become one of the most commonly used 
techniques for transcriptome profiling in a wide spectrum of biomedical and biological 
research. Analyzing bulk RNA-Seq reads to quantify expression at each gene locus is the 
first step towards the identification of differentially expressed genes for downstream 
biological interpretation. Recent advances in single-cell RNA-seq (scRNA-seq) 
 
 
technology allows cancer biologists to profile gene expression on higher resolution cellular 
level. Preprocessing scRNA-seq data to quantify UMI-based gene count is the key to 
characterize intra-tumor cellular heterogeneity and identify rare cells that governs tumor 
progression, metastasis and treatment resistance. Despite its popularity, summarizing gene 
count from raw sequencing reads remains the one of the most time-consuming steps with 
existing tools. Current pipelines do not balance the efficiency and accuracy in large-scale 
gene count summarization in both bulk and scRNA-seq experiments. In the third project, 
we developed a light-weight k-mer based gene counting algorithm, FastCount, to 
accurately and efficiently quantify gene-level abundance using bulk RNA-seq or UMI-
based scRNA-seq data. It achieves at least an order-of-magnitude speed improvement over 
the current gold standard pipelines while providing competitive accuracy.  
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CHAPTER 1. INTRODUCTION 
1.1 Cancer Biology 
The human body is made of approximately 40 trillion cells (Bianconi et al., 2013). 
Norm cells live harmoniously to form the basic units of life and together to form more 
complex tissues and organs. The functions of a cell are determined by the genetic material 
hosted within the cell in structures called chromosomes. Genes are contained in 
chromosomes that carry hereditary information stored in long strings of DNA bases, 
adenine (A), guanine (G), cytosine (C), and thymine (T). The DNA sequence in the gene 
precisely determines the unique structure and functions of each type of protein in the cell: 
DNA sequences are copied into RNA in a process called transcription; a gene that is 
transcribed is said to be actively expressed. The transcription of a gene yields an RNA 
molecule. And the base sequences in the RNA molecule are translated to synthesize 
protein. There are over 30,000 genes in the human genome. However, not all genes in a 
cell are expressed and translated into proteins. The expression of different combination of 
genes within individual cells creates structurally and functionally diverse cell types. 
Therefore, both DNA sequences and gene expression patterns control the protein synthesis 
which in turn determines the phenotypes of the cell. 
1.1.1 Cancer Genome 
Cancer arises as a result of genomic changes that have occurred in a cell. Similar 
to normal body cells, a cancer cell carries a copy of the genome from its progenitor 
fertilized egg. However, cancer cells acquire a set of different DNA sequences from the 
normal cell genome, called somatic mutations. They occur as a consequence of errors when 
cells divide or exposure to carcinogenic substances that damage DNA, such as certain 
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chemicals in tobacco smoke, radiation or ultraviolet rays from the sun. Somatic mutations 
may have several types of DNA sequence changes: 1) point mutations are single nucleotide 
variations (SNVs) affecting only one base of the gene; 2) insertions or deletions (INDELs) 
of segments of DNA; 3) copy number alterations (CNAs) are the loss or gain of genetic 
material from around 1000 bases of a chromosome to the whole chromosome; 4) 
chromosome rearrangements when a piece of a chromosome breaks and attacheds to 
another chromosome. These mutations affect the structure, function, and formation of the 
corresponding proteins. The abnormal proteins change the behavior of normal cells that 
cause healthy cells to become cancerous. For example, it iswell known that the p53 tumor 
suppressor gene is a major guardian of the cancer cell (Petitjean, Achatz, Borresen-Dale, 
Hainaut, & Olivier, 2007). p53 works actively in normal cell to prevent uncontrolled cell 
growth. But some types of mutations in the TP53 gene give rise to mutant p53 proteins that 
lose the tumor suppressive function. Cancerous cells take the advantage of the 
compromised protein function becoming more invasive, metastatic and resistant.  
1.1.2 Tumor heterogeneity 
The somatic mutations found in the genome of a cancer cell are the result of 
continuous acquisition of mutations and nature selection of cells with growth advantage 
during the lifetime of cancer development, analogous to Darwinian evolution framework. 
In cancer genomics, a clone is defined as a group of cells from the same ancestral cell. As 
a nonmalignant cell evolves to a malignant one through the continuous and random 
accumulation of genetic alterations, the stochastic nature of this process results in clones 
of cells with diverse phenotypes. Some of the changes are neutral rendering no 
consequences to the cells, while some may give rise to cell clones with different properties. 
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For example, a clone carrying errant mutations may activate growth factor signaling to 
promote survival or proliferation. Such clone can outgrow other surrounding cells causing 
the increase of the clone population. On the other hand, a clone with senescence signaling 
might be taken over by other clones leading to the declined or loss of the clone. Therefore, 
tumors are evolving overtime and space and composed of distinct cell clones, known as 
tumor heterogeneity (Burrell, McGranahan, Bartek, & Swanton, 2013). Tumor 
heterogeneity is one of the largest challenges in the cancer therapy development. Although 
there are many FDA approved cancer therapies, as well as the ones in clinical trials, there 
is no single drug likely to be effective for any cancer types. In many cases, a cancer initially 
responses to a therapy but acquires drug resistance clones over time leading to cancer 
relapse. Therefore, understanding the tumor heterogeneity is important in cancer research 
to overcome drug resistance and develop personalized medicine. 
1.2 Next-generation sequencing  
The rapid development in Next-generation sequencing (NGS) technology allows 
cancer research to comprehensively characterize the cancer somatic mutations and tumor 
heterogeneity with less cost. Traditional sequencing techniques such as the single-gene or 
array-based methods only allow the genomic exploration of limited targets in low-
throughput fashion (Meyerson, Gabriel, & Getz, 2010). For example, Sanger sequencing 
only sequences a single DNA fragment at a time. Researchers are limited to sequence small 
stretches of genomic DNA for a small number of samples due to the high cost and low 
throughput. NGS technique enables massive parallel sequencing of millions of DNA 
fragments providing a cost-effective way to screening genetic variants on thousands of 
gene with higher sensitivity, discovery power and sample throughput.  
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NGS DNA and RNA Sequencing technologies are complementary to each other in 
cancer research. Genetic mutations in cancer genome can be detected directly at DNA-
level with DNA sequencing. Since mutations on DNA-level have consequences on RNA 
transcription, gene expression analysis using RNA sequencing technique is often used to 
predict the functionality of genetic changes.  
1.2.1 DNA Sequencing 
The goal of DNA sequencing (DNA-seq) is to identify genetic irregularities on the 
genome, such as somatic SNVs, insertions, deletion, CNAs and structure rearrangement, 
that drive the growth of cancers. 
Depending on the sequencing library preparation procedures, DNA sequencing can 
be applied to the whole genome sequencing (WGS), whole exome sequencing (WES) and 
pre-selected regions of interests (gene panels). WGS provides the information of nearly 
complete DNA sequences of the genome (achieving around 95%-98% (Kamps et al., 
2017)). WES requires a library enrichment step for all exons. It offers a cost-effective way 
to survey all the protein-coding regions of the genome (known as the exome) which covers 
about 1% regions of WGS.  
WGS and WES platforms have been implemented in many large well-known 
national and international collaborations for the comprehensive characterization of the 
genomic landscape of human cancer. The Cancer Genome Atlas (Cancer Genome Atlas 
Research, 2013) (TCGA) has analyzed over 11,000 individuals representing 33 different 
types of cancers revealing common and cancer-specific somatic mutations and signaling 
pathways. International Cancer Genome Consortium(International Cancer Genome et al., 
2010) (ICGC) have collected and analyzed cancer samples globally, spanning over 76 
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projects. Such sequencing efforts have revealed genetic aberrations that promote tumor 
initiation, development, and metastasis, which has substantially advanced our knowledge 
in cancer biology. However, DNA-seq is limited in accessing the gene expression to 
evaluate the potential functional changes. 
1.2.2 RNA Sequencing 
RNA-seq addresses the limitation of DNA-seq on the transcriptome level. The 
conventional bulk RNA-seq, and most recently, single-cell RNA-seq (scRNA-seq) are used 
for sample level and cellular level gene expression profiling. The bulk RNA-seq measures 
the gene expression levels from the bulk population of millions of input cells. The resulting 
expression value for each gene is the average of all the input cells. It is often used in the 
comparative transcriptomics to measure the global gene expression changes under different 
conditions. The expression results can then be used for downstream analysis, such as cancer 
subtype classification or identifying significantly changed cancer pathways. However, 
there are also important biological questions that bulk RNA-seq is insufficient to answer. 
Cancer cells are composed of many distinct cell types and clones. It is hard to differentiate 
whether the gene expression changes are due to the cellular composition of the tumor 
sample or due to the underlying phenotype changes based on bulk RNA-seq. In these 
settings, scRNA-seq quantifying the gene expression at the single-cell level provides high-
resolution profiling for cancer studies. It has been increasingly used to discover new types 
and states of cells, and analyze the evolutionary patterns and resulting heterogeneity in 
cancer.  
The conventional RNA-seq technology has been developed more than a decade. 
The standard workflow begins with library preparation including RNA extraction, mRNA 
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enrichment, rRNA depletion and complimentary DNA (cDNA) synthesis, followed by 
NGS sequencing. It captures the expression levels of thousands of genes at once with high 
accuracy. Since RNA is extracted from groups of millions of cells, this technology is also 
known as bulk RNA-seq. Bulk RNA-seq measures the average expression level for each 
gene across all the cells. They provide vast amount of information for comparing gene 
expression differences in multiple conditions, e.g., tumor vs normal tissues, treated vs non-
treated response as well as identifying cancer biomarkers. Bulk RNA-seq design assumes 
that cells for a given tissue in question are homogenous and gene expression averages 
across a pool of cells. This process ignores cell-to-cell variability and drops cell-level 
information which makes it insufficient for studying the heterogeneous tumor cell system. 
In recent years, technical advancement in NGS and cell separation methods has 
made the gene expression profiling at cellular level possible using single cell RNA-seq 
(scRNA-seq). Several modern scRNA-seq platforms have been developed, such as 10X 
Chromium, DropSeq and Fluidigm C1, capable of profiling hundreds to thousands of 
individual cells at once. Those methods use Unique Molecular Identifiers (UMIs) and cell 
barcodes and have been optimized for single cell expression profiling with low starting 
amounts of RNA. One of the key steps in scRNA-seq is cell isolation where cells can be 
physically separated using fluorescence-activated cell sorting (FACS) or they can be 
trapped inside hydrogel droplets. Next, within each isolated cell, RNA molecules are 
extracted and tagged with UMIs and Cell barcodes. Then cells break to release the mRNAs 
for pooled PCR amplification and sequencing. The UMIs and Cell barcodes are important 
single cell specific information used in the data analysis. Each mRNA within a cell is 
tagged with a cell barcode. A cell barcode is unique to each cell, it tells which cell the 
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mRNA is from. In order to trace the cellular origin, each cDNA molecule from the same 
cell is labeled with a cell barcode, which is an oligonucleotide sequence unique to the cell, 
before pooled library preparation. This allows early pooling of thousands of samples and 
increases the sequencing throughput and allow to computationally recover the mRNAs for 
a specific cell after the pooled PCR amplification step. Moreover, due to the small amount 
of starting material in each cell, scRNA-seq requires a PCR amplification step for cDNAs. 
This procedure increases the sensitivity of the scRNA-seq, but on the other hand, PCR 
duplicates can not be identified simply based on the reads mapping position. By tagging 
the cDNAs with UMIs, sequences with the same UMI can be detected as PCR duplicates. 
Therefore, by adding UMIs and cell barcodes in scRNA-seq library preparation, PCR 
duplicates and cell origins can be computationally identified enabling sensitively measure 
the cellular-level expression differences. 
1.3 Current Computational Methods for Cancer Genomics Data Analysis 
Cancer genomics is a new research area that applies the rapid technological 
development NGS technology to identify the somatic mutations, cancer driver genes, 
understand cancer biology and find new methods for cancer diagnosis and treatment. NGS 
allows researchers to interrogate the cancer genome in great resolution, high accuracy and 
low costs.  In the past decade, many NGS approaches have been developed for cancer study 
to solve the puzzles in DNA and RNA levels. Parallel with the rapid advancement in NGS 
technologies is the development of novel algorithms for NGS data analysis. 
1.3.1 Somatic mutations analysis 
Identifying somatic mutations is the key step in cancer genomics for the 
characterization of a cancer genome. Majority of the somatic mutation calling protocols 
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require sequencing of matched tumor and normal samples from the same cancer patient 
using WES or WGS sequencing technique. Somatic mutation calling consists of mainly 
four components: read preprocessing, variant calling, variant filtering and variant 
annotation. 
Before mutation calling, the resulting FASTQ files are preprocessed to generate 
high quality analysis-ready Binary Sequence Alignment Map (BAM) file. The quality 
control (QC) step is performed on the raw FASTQ files to remove poor quality bases and 
non-biological sequences (not originated from the sample). Reads passing the QC are 
mapped to a reference genome using read alignment algorithms. PCR duplication, which 
are reads originating from the same fragment of DNA, can then be detected based on the 
alignment position in the BAM file. Reads are ranked by their base-quality scores to 
determine the primary and duplicate reads. Duplicate reads are marked with the 
hexadecimal value of 0x0400 in the BAM file and will not be included in the variant calling 
algorithms. The BAM files from the matched tumor and normal samples are subjected to 
local realignment around insertions and deletions to correct mapping errors resulted from 
the read aligner and the regions contain INDELs. Since many variant calling algorithms 
rely heavily on the per base quality score reported by the sequencer in the BAM files, base 
quality score recalibration is required to correct the over- or under-estimated base quality 
due to various sequencing technical errors from the sequencer. Pre-processed BAM files 
are passed to somatic variant calling algorithm for somatic mutation detection. There are 
various tools publicly available covering a wide spectrum of application in somatic point 
mutations, INDELs and CNAs calling. Post-filtering of candidate somatic mutations is 
often required to reduce false positive calls generated due to the NGS artifacts, read 
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alignment errors and low-quality samples. For example, reads generated by the Illumina 
platform are commonly affected by the strand bias artifacts, where the heterozygous 
genotype can only be observed on one specific strand (Guo et al., 2012). Many variant 
calling pipelines compute strand bias scores and use it as a filter to improve the specificity. 
1.3.2 Driver mutations 
Somatic mutation analysis pipeline for WES/WGS on an individual cancer reveals 
hundreds to thousands of somatic mutations present in the cancer genome. One of the major 
challenges is to prioritize those somatic mutations to identify the ones casually implicated 
in cancer. These mutations, known as driver mutations, contribute growth advantage in 
cancer initiation and development, turning on specific pathways promoting cancer. 
Deciphering driver mutations is the key to design rational therapeutics aimed at specific 
cancer phenotypes, predict patient response to traditional treatments, and expanding the 
pool of patients likely to benefit from existing treatments. However, beside the driver 
mutations, there are a larger fraction of somatic mutations that do not involve in the 
development of cancer. These non-functional mutations, often known as passenger 
mutations, happen randomly in cancer cells that have already acquired driver mutations in 
the cancer genome. They will be passed to descendants during the cancer cell divisions and 
present in the final cancer cells. Therefore, differentiating the driver mutations from 
passenger mutations is the main goal for many cancer studies. Despite a few exceptions, 
most driver mutations occur in only a small fraction of tumor samples. Therefore, 
identifying these low recurrent driver mutations that are buried among a vast pool of 
passenger mutations is challenging.  
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1.3.3 RNA-seq Analysis 
Analyzing RNA-seq reads to quantify expression at each gene locus is the first step 
towards any downstream biological interpretation. There are two popular gene expression 
estimation approaches for bulk RNA-seq: gene count and transcript abundance. Gene count 
is essentially the total number of reads sequenced within a gene. Many popular statistical 
differential expression methods such as DESeq2 (Love, Huber, & Anders, 2014) and edgeR 
(Robinson, McCarthy, & Smyth, 2010) take gene count as input. They model it as negative 
bionomial distribution to deal with biological variability and overdispersion and 
determines differential expression using exact tests (Seyednasrollah, Laiho, & Elo, 2015). 
Several tools such as featureCounts (Liao, Smyth, & Shi, 2014) and HTSeq (Anders, Pyl, 
& Huber, 2015) are used to obtain the gene counts. These tools require several 
preprocessing steps on the raw FASTQ file from the sequencing before performing read 
counts: 1) generally, a read trimming step is necessary to remove adapter sequences and 
low-quality bases from the FASTQ files (Bolger, Lohse, & Usadel, 2014; Martin, 2011a). 
This improves the mappability of the reads during the downstream alignment step. The 
quality trimming criteria, such as minimum base quality score or the number of bases to be 
trimmed on start or end of each read, are selected empirically by the users. 2) trimmed 
reads are aligned to either the reference genome or the reference transcriptome using RNA-
seq mappers, to generate the BAM files. 3) aligned reads in the BAM files are assigned to 
genes based on the genomic locations provided in the Gene Annotation File (GTF) for 
gene-/transcript-level read counts. Although there are some efficient algorithms available 
to summarize read counts from the BAM file, read alignment is computationally heavy, 
requiring large memory and CPU time. Alternatively, read counts can be estimated from 
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transcript abundance, by first assigning reads to transcripts using transcript-level 
annotation, and summarizing read counts at transcript-level. The gene-level expression can 
then be estimated using tools specially designed for summarizing the transcripts counts to 
gene counts correcting effective gene length differences across samples (Soneson, Love, 
& Robinson, 2015).  
The scRNA-seq gene expression analysis can safely borrow the tools and pipelines 
that have been developed for bulk RNA-seq. Similar to bulk RNA-seq, reads are first 
aligned to the reference genome/transcriptome, and then assigned to genes or transcripts 
depending on the selected algorithms. However, after the read assignment, there are 
additional single-cell specific steps required for carefully analyzing the data. By 
introducing UMIs for each cDNA molecule, reads originated from the same molecule will 
have the same UMI sequence, allowing computationally deduplicate reads to reduce the 
amplification bias. So instead of counting the number of reads assigned to each gene, 
scRNA-seq aims at counting the number of unique UMIs. The UMI collapsing procedure, 
in which reads assigned to the same gene with identical UMIs are only counted once, is 
performed. However, the UMI counts are often overestimated due to the sequencing/PCR 
errors within the UMI sequences. Therefore, error correction for UMIs is necessary before 
collapsing reads to UMIs. Another aspect that complicates the analysis is cell barcoding. 
cDNAs from the same cell are tagged with a cell-specific sequence, cell barcode, to identify 
cells and at the same time, allow the sequencing of thousands of cells in a single run. 
Sequencing errors on the cell barcodes not only overestimates the actual number of cells 
in the sample, but also may underestimate the UMI counts for the affected cell. Current 
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analysis pipelines will filter the low sequencing quality barcodes and barcodes with low 
read count to reduce such errors in the downstream analysis. 
1.4 Contribution 
The aims of the dissertation are to develop novel bioinformatics methods for 
resolving several challenges in large-scale cancer genomics study covering sample-level 
gene mutation analysis and single-cell level gene transcriptome analysis. We assess the 
performance of methods in the completed projects and demonstrate their application in 
cancer genomics research.  
High-throughput, robust and reproducible Bioinformatics framework for 
somatic mutation calling. We developed user-friendly Snakepipe framework for 
systematically processing the raw whole -exome/-genome sequencing data for 
somatic/germline mutation detection. Snakepipe abstracts the complexity of the analytical 
pipeline, parameters selection and computation environment deployment from the users. It 
ships with automated NGS best practices pipelines enabling direct “sequence-to-report” 
data transformation and requires minimun user configurations. All the analytical softwares 
are precompiled and packaged into Docker containers allowing cross-platform pipeline 
execution and built-in version controls for reproducibility. Snakepipe scales well to cloud 
and HPC infrastrutture for processing large-scale genomics data using distributed 
computation resources and parallel computing. Snakepipe provides automatic failure 
recovery in cases of unplanned hardware errors or system downtime. Moreover, new 
analytical modules can be easily developed and integrated to the existing pipelines. 
Efficent mututally exclusive testing for genome-wide drive mutation detection. 
We developed MEScan, one of the first tools to allow de novo screening of mutually 
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exclusive patterns at the genome scale. The core component of MEScan is a test statistic 
directly quantifies the discrepancy between the observed level of mutual exclusivity and 
the expected value due to the background, taking into accout for the backgroud mutation 
rate heterogeneity and unbalanced mutation patterns. Comparing to other methods, 
MEScan offers more power in detection of true mutually exclusive patterns even under the 
conditions with low read coverage and is at least two orders of magnitude faster than the 
existing methods. We extend MEScan with Markov chain Monte Carlo (MCMC) algorithm 
to efficiently screen for mutually exclusive gene sets at the genome scale with a 
summarization procedure to select high-confidence findings. MEScan has been applied to 
GBM, BRCA, LUSC, OV and PanCancer to identify cancer-specific driver mutations. 
 Alignment-free gene count quantification for bulk and single cell RNA-seq. 
RNA-seq has been widely used in cancer research for differential gene expression between 
samples using bulk RNA-seq and more recently for characterizing differential gene 
expression at cellular level and studying tumor heterogeneity using scRNA-seq. Although 
many algorithms have been published, they either have high computational costs in terms 
of time and resources, or they are designed for transcript-level abudance estimation which 
requires additional downstream processing for gene-level abudance conversion. Moreover, 
since most scRNA-seq library protocols have strong 5’ or 3’-end bias and are sequenced 
with low coverage, assigning reads to transcript-level features in scRNA-seq is much more 
difficult than for gene-level. Therefore, we developed a novel alignment-free gene 
expression quantification algorithm FastCount that performs gene-level expression 
analysis for both bulk and single cell RNA-seq . It avoids the time-consuming base-wise 
alignment step and classifies reads to gene using gene-specic k-mer signatures. Comparing 
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with other methods, it is over an order-of-magnitude faster than the existing gold standard 
algorithms  while achieves very competitive accuracy.  
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CHAPTER 2. Bioinformatics Framework for Characterization of Squamous Cell Lung 
Cancers from Appalachian Kentucky 
Comprehensive characterization of cancer genomics relies heavily on the 
bioinformatics pipelines to analyze the massive production of genomic, transcriptomic, 
epigenomic and proteomic NGS data. Currently pipelines are either not executable cross-
platform or not easily customizable to extend for new analysis modules. In this project, we 
present an open-source, modular computational framework to perform high-throughput, 
robust and reproducible bioinformatics analyses of cancer genomic data. It automates best 
practice data analysis pipelines, requires minimum configurations from the users and 
provides publication-ready figures. We have applied this framework for the 
characterization of squamous cell lung cancers from Appalachian Kentucky using WES 
data and have identified distinct genomic landscape and potential therapeutic markers. 
2.1 Introduction 
NGS has a broad spectrum of applications in cancer genomics, however, the 
bioinformatic analysis which involves in the transformation of the raw “ATGC” sequence 
to meaningful genomic information such as gene expression abundance or gene mutations 
is a non-trivial work. NGS generates millions of DNA sequences for a single sample. The 
raw DNA sequences are used as source input for cancer biologist to answer various 
biological questions. Bioinformatics pipelines, which consist of a series of computational 
software to systematically process the large number of genomic data, have become the 
power horse for cancer research. However, most researchers have no capacity to perform 
large-scale analyses on the NGS data sets using appropriate tools and pipelines. This has 
sparked the need for the development of various analysis pipelines and platforms. In the 
past few years, there are a variety of analysis pipelines being published such as Galaxy 
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(Goecks, Nekrutenko, Taylor, & Galaxy, 2010), bcbio-nextgen 
(https://github.com/bcbio/bcbio-nextgen), Taverna (Wolstencroft et al., 2013), Toil 
(https://github.com/bd2kgenomics/toil), The Cancer Genomics Cloud (Lau et al., 2017), 
DNAnexus (http://dnanexus.com), Firehose (http://firebrowse.org/) and many others. They 
differ in the analysis procedures, tools selection, parameter configurations as well as 
computational environment. Although current bioinformatics pipeline platforms provide 
good support to perform data analyses using the built-in modules, customizing and 
extending the pipelines to meet various research requirements are very difficult. Galaxy 
(Goecks et al., 2010) platform is a web-based approach that enables researchers with 
Internet access to perform genomic data analyses through a web page interface. Galaxy 
users can create analysis pipelines using the interactive, graphical editor by simply 
connecting software modules pre-wrapped by Galaxy. A similar web-based tool, Taverna, 
is a workflow management platform, that allows users to define and execute workflows 
from a web portal. Those platforms, though very helpful for scientists without 
programming or informatics expertise, have several limitations. For example, users are 
limited to the number of tools and analyses collected by the platforms; non-programmer 
users must wait for the platform updates to apply new algorithms on their data; 
programmatic access to service is not available for advanced users. bcbio-nextgen is a 
powerful python toolkit for users with extensive programming knowledge. bcbio-nextgen 
optimizes each analytical pipeline and software for improved computational performance 
handling job distribution, idempotent processing restarts and safe transactional steps. 
However, the pipeline customization and development are challenging and complicated 
even for users with programming background. Cloud-based commercial service providers, 
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such as The Cancer Genomic Cloud and DNAnexus, offer flexible high-performance 
computing resources for large-scale collaborative research national and international wise. 
Both web interfaces and programming APIs are available for users for conveniently 
submitting and monitoring automated large batch analyses. Users can rent the computing 
resources such as virtualized computers, data storage and bandwidth on demand and pay 
for the exact resources used. However, the cloud-based service is currently not an option 
for small labs or institutes with limited funding resources.  
NGS data analysis has been a very active research field. A large number of 
bioinformatics tools have been published covering every step in the data analysis pipeline. 
Novel algorithms have continuingly been developed to aid in discovery of new findings in 
the data, or to improve the performance of existing algorithms. It is challenging for caner 
biologists to appreciate all the steps and select appropriate tools necessary to conduct the 
data analysis properly. A basic somatic mutation calling pipeline based on WES would 
contain as few as 12 steps from raw sequence preprocessing to the final somatic mutation 
calling. For each individual step in the pipeline, there are collections of tools specially 
designed for accomplishing the data transformation. The number of bioinformatics tools to 
choose from can be overwhelming. In the past decades, over 30 somatic SNV callers have 
been published by different research groups (C. Xu, 2018). They differ considerably in 
terms of the core algorithms, filtering criteria, and output. Samtools (H. Li, 2011) uses 
Bayesian approaches to calculate the log-likelihood ratio of tumor and normal samples 
having the same genotype. Varscan2 (Koboldt et al., 2012) relies on heuristic approaches 
to identify variants with supporting reads meeting certain thresholds. Then it applies 
Fisher’s exact test on the contingency table of read counts to isolate somatic variants based 
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on the p-value. Samtools and Varscan2 can report both SNVs and INDELs. Varscan2 can 
also infer the relative copy number changes in tumor sample by performing pairwise 
comparison of the read depth between the tumor and its matched normal samples. Mutect 
(Kristian Cibulskis et al., 2013) is based on the Bayesian classifier approach, but instead 
of modeling the joint genotypes in the tumor and normal samples, it uses joint allele 
frequencies to take into account the presence of heterogenous subclones in the tumor 
sample. Therefore, a pipeline that employs the standardized best practices workflows and 
analytic tools provide a guide for cancer researchers. 
Lastly, analyzing data in large scale and collaborative studies requires a cross-
platform, scalable and reproducible pipeline management system. From 2012 to 2017, the 
amount of genomic data in the Sequence Read Archive (SRA) has doubled four times. 
Such data archives are comprehensive enough to allow researchers to ask and answer a 
broad range of sophisticated questions without generating new data. Re-analyzing large 
collection of data requires pipelines to be easily adapted on different commercial clouds 
such as Google Cloud Platform, Amazon AWS and Microsoft Azure or academic high-
performance computing (HPC) clusters. Large collaboration projects and consortiums 
require standardized and reproducible pipelines to make sure that each participant will 
produce the same outputs given the same input data. ICGC, for example, is a large 
collaboration on cancer research. More than 25,000 cancer omics data at the genomic, 
epigenomic and transcriptomic levels will be collected and analyzed globally to reveal the 
repertoire of oncogenic mutations, uncover traces of the mutagenic influences, define 
clinically relevant subtypes for prognosis and therapeutic management, and enable the 
development of new cancer therapies (International Cancer Genome et al., 2010). 
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Reproducible analyses among the collaborators are non-trival. It requires a standard way 
to specify all the pipeline dependencies and execution environments for simplifying 
deployment, sharing and reusing of tools between research groups.  
Snakepipe provides a user friendly bioinformatics pipeline framework. It ships with 
automated NGS best practices pipelines for analysing WES and WGS data for 
germline/somatical mutation calling and requires mimimun configurations on the user end. 
Snakepipe enables direct “sequence-to-results” transformation. It natually determines the 
dependencies and tools for each individual steps and jobs are distributed to the work nodes 
for serialized or parallel processing. Once the analyses are complete, Snakepipe 
automatically collect the input source files, user configurations and results in a compressed 
format for backup and reproducible research collabration. New pipelines and functions can 
be easily developed and integerated to the existing ones in the Snakepipe framework by 
containerization of bioinformatics tools and job definitions in simple python-like scripts.  
The overall workflow for mutation calling is comprised of raw seqeuecning read 
preprocessing, mutation calling, significantly mutated genes identification, CNA calling, 
cohort comparison, clinical actionable mutation prediction as well as comprehensive 
results visualization. 
2.2 Pipeline management 
The pipeline framework adopts a modern workflow management engine, 
Snakemake (Koster & Rahmann, 2018) and docker containers. The Snakemake engine 
defines each pipeline in a “Snakefile” using a domain-specific language. It adopts the rule 
concept used by the GNU Make (Stallman RM, 1991), with extended functionalities and 
flexibilities. The analysis steps of a pipeline are composed of corresponding rule 
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definitions.  A regular rule expresses 1) input files 2) output files and 3) a shell command 
or scripts using other programming languages (such as Python or R scripts) which describes 
how the output files are generated given the input files. In order to naturally represent the 
plan of job executions and job dependencies in a workflow, Snakemake uses a directed 
acyclic graph (DAG), where a vertex is the execution of a job defined by a rule and a 
directed edge indicates the execution sequence of the 2 jobs. A job on the ending vertex of 
each edge requires the input from the job on the starting vertex of the edge. Therefore, a 
path which is the sequence of edges in the DAG serializes the execution order of the 
individual jobs in the workflow. Snakemake has the following properties: i) it 
automatically detects the rules required for the completion of the final workflow; ii) jobs 
on disjoint paths can be run in parallel; iii) it only executes rules with missing output files 
or changes of the input file modification time to avoid re-running the completed jobs and 
for failure recovery; and iv) jobs can be executed locally and distributed to accessible 
computing resources, such as cloud or HPC.  
2.3 Runtime environment deployment 
The analytical tools required in the workflow are managed using docker containers 
to simplify the deployment of the pipeline under different computing environments, for 
version control and research reproducibility. Each program and all its dependencies are 
packaged into a docker container tagged with a unique version id. The docker images are 
hosted on Docker Hub and can be easily shipped to any machine, either cloud or local. 
Setting up the tools from scratch only needs minimal configuration of Docker or 
Singularity. Snakepipe will infer the necessary container images based on the types of the 
NGS data and automatically pulls the images from the Docker Hub. The pipeline is portable 
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and robust that enables reproducibility, transparency and shareability. It can be easily 
deployed and executed cross-platform such as local workstations, HPC and cloud 
platforms. 
2.4 Best practice workflows 
Snakepipe WES/WGS data analysis pipeline for germline/somatic mutation calling 
(Error! Reference source not found.) is developed based on the recommended best 
practice from Broad Institute using the Genome Analysis Toolkit (Aaron McKenna et al., 
2010) (GATK). Sequencing reads were trimmed and filtered using Cutadapt (v1.4.1) 
(Martin, 2011b), then aligned to human reference genome b37/hg19 using BWA (v.0.7.9a) 
(H. Li & Durbin, 2010). PCR duplicates were removed using Picard 
(http://broadinstitute.github.io/picard/, v1.115). The Genome Analysis Toolkit (GATK 
v3.1-1) (A. McKenna et al., 2010) was used for local indels realignment and base quality 
recalibration. Somatic point mutations and indels were detected using MuTect (v1.1.4) (K. 
Cibulskis et al., 2013) and SomaticIndelDetector (GATK v2.3-9), respectively, with 
default settings. Mutations were annotated using Oncotator (v1.4.1.0) (Ramos et al., 2015). 
Significantly mutated genes were identified using MutSigCV (v1.4) (Michael S. Lawrence 
et al., 2013). Somatic copy-number alterations (SCNA) analysis was conducted using 
ExomeCNV (Sathirapongsasuti et al., 2011), an R statistical package. Exonic CNAs were 
inferred based on the depth-of-coverage ratio between matched tumor and normal samples. 
Then, CNAs calls were combined into larger segments using circular binary segmentation 
in DNAcopy (Venkatraman E. Seshan). Gistic2.0 (Mermel et al., 2011) with a confidence 
level of 0.95 was used on the copy ratio profiles to identify significantly amplified/deleted 
regions. To evaluate the clinical relevance of the somatic genomic alterations identified in 
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our cohort, we downloaded the OncoKB database (Chakravarty et al., 2017) (accessed in 




Figure 1 Whole exome sequencing data analysis pipeline for somatic mutation calling and 
copy number variation detection.  The pipeline contains two major parts: 1) preprocessing 





We applied the Snakepipe to analyze the WES of 51 SQCC patients from AppKY, 
which includes an overview of somatic alterations and copy-number variations, explores 
unique mutational patterns, and provides a clinically actionable assessment of mutations in 
this population.  Essential to this effort was the full sharing of the comprehensive genomic 
profile of lung SQCC in TCGA (The Cancer Genome Atlas Research Network, 2012), 
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which provided the comparison of the initial 178 subjects from a US genomic profile that 
does not focus on Central Appalachians.  
2.5.1 Overview of somatic alterations 
The mean coverage of WES across the targeted regions was 104× with 92% of 
targeted bases being covered at ≥ 30×. Raw sequencing data are available at dbGaP 
(Accession: phs001651.v1.p1). We identified 16,005 somatic single-nucleotide variants 
and 217 somatic insertions or deletions (indels) across 51 matched tumor and normal pairs 
in the protein coding regions. Of those mutations, 12,117 were predicted to be non-silent 
mutations resulting in an amino acid change. The mean mutation rate in our cohort was 
237 non-silent mutations per patient, corresponding to 8.5 mutations per megabases (Mb). 
Among non-silent mutations, transitions and transversions at CpG sites were the most 
commonly observed mutation types, with rates of 11.5 per Mb and 15.5 per Mb, 
respectively. For non-CpG sites, transitions were more frequently observed at C:G sites 
(3.2 per Mb) than at A:T sites (1.8 per Mb). Similarly, transversions were more frequently 




Figure 2. Significantly mutated genes in lung SQCC. Significantly mutated genes 
(FDR<0.2) from whole-exome sequencing of 51 samples from Appalachian Kentucky 
patients.The number and percentage of samples with mutations in each gene are shown on 
the left. Samples are displayed as columns, with the overall number of mutations, smoking 
status, and tumor stage plotted at the top. 
 
2.5.2 Significantly mutated genes 
We identified 3 genes that were significantly mutated (i.e., non-silent mutation rates 
higher than background mutation rates) in the AppKY cohort with an FDR < 0.2 using 
MutSigCV (Michael S. Lawrence et al., 2013): TP53, PCMTD1 and IDH1. To increase the 
statistical power of our analysis, we followed the approach of the TCGA SQCC report 
(2012) and performed a secondary MutSigCV (M. S. Lawrence et al., 2013; Michael S. 
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Lawrence et al., 2013) analysis to only consider genes causally implicated in cancer 
according to the COSMIC database (Futreal et al., 2004). This approach enabled us to 
identify 11 additional genes that were significantly mutated with an FDR < 0.2: PIK3CA, 
RNF43, MLLT10, STK11, NFE2L2, DEK, POT1, ATP2B3, HRAS, HOXA11 and HOXA13 
(Figure 2).  
 
Figure 3 GISTIC amplification (left) and deletion (right) plots of the G-scores (shown at 
the top of the figure) and q-values (shown at the bottom of the figure) across the entire 
region analyzed. 
 
2.5.3 Copy number variation analysis 
SCNAs were analyzed using WES data. We identified regions with significant 
SCNAs using Gistic2.0 (Mermel et al., 2011). There were 18 peaks of significant 
amplification and 34 peaks of significant deletions (FDR<0.25). Significantly amplified 
regions were 3q27 (MCF2L2), 8p11 (FGFR1, TACC1, WHSC1L1, LETM2, RNF5P1), 
26 
 
11q13 (CCND1-oncogene), 7q21.2 (CDK6), 19q13, 13q34, 5p15, 8q24 (MYC-oncogene) 
and deleted regions were 9p21 (CDKN2A-tumor suppressor, CDKN2B), 8p23, 10q23 
(PTEN, CFL1P1, KLLN), 17p13, 4q28.2 (VEGFC), 22q13.2 (CHEK2). Consistent 
amplification patterns were seen in certain related sets of genes, such as stem cell renewal 
genes. 
2.5.4 Comparative mutational analysis with other cohorts 
We first compared somatic mutations and SCNAs of AppKY lung SQCC to TCGA 
cohort (Campbell et al., 2016; Kim et al., 2014; C. Li et al., 2015; The Cancer Genome 
Atlas Research Network, 2012). We focused our comparison on significantly mutated 
genes in at least one cohort by the MutSigCV (M. S. Lawrence et al., 2013) analysis. Our 
comparative analysis presented here (Table 1) included somatic mutations (point mutations 
and indels) only in the calculation of gene alteration rate. Both cohorts showed similar rates 
of alterations for TP53 (68.6% AppKY, 80.9% TCGA, FDR q-value=1.000), PIK3CA 
(11.8% AppKY, 15.7% TCGA, FDR q-value=1.000), NOTCH1 (11.8% AppKY, 8.4% 





Table 1. Somatic alteration rate comparison between AppKY and TCGA of Lung SQCC.  
The comparison focuses on genes that were identified as significantly mutated based on 
the MutSigCV analysis in at least one of the two cohorts.  
 
Hugo Symbol* AppKY (%) TCGA (%) p-value§ q-value¥ 
IDH1○K  11.80% 1.10% 0.002 0.039 
PCMTD1○K  17.60% 3.90% 0.002 0.045 
DEK 5.90% 0.00% 0.011 0.200 
NFE2L2⊕ 3.90% 15.20% 0.032 0.584 
CDKN2A○T  3.90% 14.60% 0.050 0.830 
HOXA11 3.90% 0.00% 0.049 0.830 
TP53⊕ 68.60% 80.90% 0.082 1.000 
PTEN○T  5.90% 7.90% 0.770 1.000 
PIK3CA⊕ 11.80% 15.70% 0.655 1.000 
KEAP1○T  9.80% 12.40% 0.806 1.000 
KMT2D○T  9.80% 19.70% 0.142 1.000 
HLA-A○T  7.80% 3.40% 0.236 1.000 
NOTCH1○T  11.80% 8.40% 0.424 1.000 
RB1○T  2.00% 6.70% 0.307 1.000 
RNF43 5.90% 1.70% 0.126 1.000 
MLLT10 7.80% 3.90% 0.269 1.000 
STK11 3.90% 1.70% 0.309 1.000 
POT1 5.90% 2.20% 0.186 1.000 
ATP2B3 3.90% 2.20% 0.617 1.000 
HRAS 5.90% 2.80% 0.381 1.000 
HOXA13 3.90% 0.60% 0.125 1.000 
*○K : significantly mutated in AppKY only; ○T : significantly mutated 
in TCGA only; ⊕: significantly mutated in both cohorts 
§ The p-value was based on the Fisher’s exact test to compare 
percentages of samples that had somatic alterations (somatic mutations 
or SCNAs) in the two cohorts. 
¥ The q-value was based on the Benjamini–Hochberg procedure. 
Genes with significant differences (FDR<0.2) in the alteration rate are 
shown in bold. 
 
Significant differences in mutation rates between the AppKY and TCGA cohorts 
were observed. The IDH1 mutations were observed in 11.8% of patients in the AppKY 
cohort. In contrast, only 1.1% of patients in the TCGA cohort had IDH1 mutations (FDR 
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q-value=0.039). Similarly, the AppKY cohort also showed a higher rate of mutations in 
PCMTD1 (17.6% AppKY vs. 3.9% TCGA, FDR q-value=0.045). Even after adjusting for 
age, gender, stage, and smoking via exact logistic regression, mutation frequencies are still 
significantly different between the AppKY and TCGA cohorts for IDH1 (p-value=0.0024) 
and PCMTD1 (p-value=0.019).  
2.5.5 Clinically actionable mutations assessment 
We investigated the somatic mutations/SCNAs observed in our cohort in 
association with FDA approved agents or published or ongoing clinical trials for non-
small-cell lung carcinoma (NSCLC) or other tumor types. 5 subjects (10%) had actionable 
mutations, defined as FDA approved drugs (either for this indication or another cancer 
type), with a total of 8 somatic mutations/SCNAs events found in these 5 individuals. 
Additionally, we found that 33 out of 51 subjects (65%) had high (>20 mut/MB) or 
intermediate (6-20 mut/MB) tumor mutation burden (TMB), indicating an additional group 
of therapeutic choices for this population using checkpoint inhibitors. Overall, 65% of 
subjects had actionable mutations with FDA approved drugs and/or TMB that was high or 




Table 2. Clinically actionable mutations identified for APPKY patients. 
Gene Patient Mutation Drug DrugLevel 
ERBB2 MCC-51 Amplification 
Trastuzumab;Neratinib; 
Lapatinib + Trastuzumab,  
Pertuzumab + Trastuzumab,  
Ado-trastuzumab emtansine, 
 Lapatinib, Trastuzumab 
1;3A;1 















PDGFRA MCC-12 Amplification Imatinib 2A 
PDGFRA MCC-36 Amplification Imatinib 2A 
PDGFRA MCC-47 Amplification Imatinib 2A 
TSC2 MCC-7 Deletion Everolimus 2A 
HRAS MCC-7 c.181C>A Tipifarnib 4 
NF1 MCC-2 c.55G>T LTT462, Binimetinib, BVD523, Trametinib 4 
HRAS MCC-12 c.34G>A Tipifarnib 4 
BRAF MCC-19 c.1391G>T LTT462, BVD-523, KO-947 4 





PTEN MCC-47 c.367C>T GSK2636771, AZD8186 4 
HRAS MCC-49 c.37G>C Tipifarnib 4 
NOTCH1 MCC-21 Deletion PF-03084014 4 
NOTCH1 MCC-29 Deletion PF-03084014 4 
HRAS MCC-49 Amplification Tipifarnib 4 





PTEN MCC-2 Deletion GSK2636771, AZD8186 4 










HRAS MCC-40 Amplification Tipifarnib 4 
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PTEN MCC-9 Deletion GSK2636771, AZD8186 4 
BRAF MCC-19 Amplification LTT462, BVD-523, KO-947 4 
PTEN MCC-33 Deletion GSK2636771, AZD8186 4 
Note: The drug level is defined by OncoKB. Levels 1 and 2 are FDA approved drugs. 
  
2.5.6 Prediction of the effect of IDH1 mutations  
 
Figure 4. IDH1 and PCMTD1 mutations. (A) IDH1 mutations and their mutation 
frequencies (circles). (B) PCMTD1 mutations and their frequencies (circles). 
 
Mutations in IDH1 and its homolog IDH2 coding for cytosolic and mitochondrial 
isocitrate dehydrogenases, correspondingly, are common in gliomas (Yan et al., 2009) and 
myeloid neoplasms (Molenaar et al., 2015), but rare in lung cancer. We observed multiple 
IDH1 variants: R132H, V178A, A307S and L352P (Figure 4A), and the R132H variant 
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was confirmed by immunohistochemistry. The IDH1 variant R132H is reported in a variety 
of cancers and the role of various R132 missense substitutions has been studied 
extensively. These mutations are generally heterozygous, suggesting a gain-of-function by 
the enzyme, and supported by mechanistic studies demonstrating that the R132H variant 
protein has an aberrant enzymatic activity, converting α-ketoglutarate (2OG) to (R)-2-
hydroxyglutarate (2HG) (Dang et al., 2009). This enantiomer of 2HG acts as an 





Figure 5. Functional analysis of IDH1 variants.  (A) Segments of multiple sequence 
alignment for representative IDH1 (upper set) and IDH2 (lower set) orthologs, showing 
conservation of Arg132, Val178, Ala207, and Leu352. Numbers are provided for a human 
IDH1 protein. A complete alignment and sequence accession numbers are shown in Figure 
7. Positions 132, 178, 307, and 352 are marked and highlighted in yellow, whereas 
substitutions in these positions are highlighted in blue. For all other positions, residues that 
are identical to those in the human IDH1 are highlighted in gray. Human, Homo sapiens; 
Frog, Xenopus tropicalis; Fish, Takifugu rubripes; Nematode, Caenorhabditis elegans, 
Worm, Saccoglossus kowalevskii; Lancelet, Branchiostoma floridae. (B) Effect of IDH1 
variants on enzyme activity. Left: effect of R132H and A307S mutants; Right: effect of 
V178A and L352P mutants. The two-sample t-test was performed to compare each IDH1 
mutant versus the wild type and the Bonferroni correction was used for multiple 
comparison adjustment. • Statistically significant reductions of NADPH production 
comparing IDH1 R132H versus wild type; ♦Statistically significant reductions of NADPH 




To understand potential consequences of the other detected IDH1 variants (V178A, 
A307S, and L352P), we applied a recently developed evolutionary approach (Adebali, 
Reznik, Ory, & Zhulin, 2016), based on the principle that most deleterious, and hence 
potentially disease-promoting mutations, result in reduced evolutionary fitness and thus are 
selected against during evolution. Homologous genes derive from a common ancestor 
gene, while orthologous genes diverge after a speciation event in two different species; 
paralogous genes occur within a single species and diverge after a duplication event. Unlike 
orthologous genes, a paralogous gene evolves new function(s), making the distinction 
between the roles of orthologous and paralogous genes in disease critical for estimating 
disease risk using molecular conservation (Adebali et al., 2016). We have identified both 
IDH1 and IDH2 orthologs in representative genomes from all major eukaryotic 
supergroups and built a maximum-likelihood phylogenetic tree (Figure 6) from their 
multiple sequence alignment (Figure 7). Satisfactorily, we found that position 
corresponding to R132 in the human IDH1 protein is absolutely invariant, not only in 
orthologous sequences, but in all IDH homologs (Figure 6), which is consistent with 
deleterious effects of its substitution. Similar to R132, both A307 and L352 are also 
invariant residues in all IDH1 and IDH2 orthologs and all other IDH1 homologs with 
uncertain evolutionary history from all major eukaryotic supergroups (Figure 5A and 
Figure 7). Because no substitutions in these positions occurred since the last eukaryotic 
common ancestor, any changes in these positions were predicted to be disease-promoting. 
While position V178 is not invariable among all homologs, the only allowable substitutions 
are V178I (occasionally found in both IDH1 and IDH2) and V178C (occasionally found 
only in IDH2) (Figure 5A and Figure 7). No V178A substitution was ever detected in any 
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IDH homologs, including the most distant ones, and might be cancer-promoting. We 




Figure 6. Maximum likelihood phylogenetic tree of IDH1 and IDH2 proteins from a 
representative genome set.  Clades of definite IDH1 and IDH2 orthologs are highlighted in 
green and magenta, correspondingly. Multiple sequence alignment was used to construct 
the tree and sequence accession numbers are shown in Figure 7. Human proteins are 






Figure 7. Multiple sequence alignment of IDH1 and IDH2 proteins from a representative 
genome set.  Sequence labels and the order of sequences correspond to that of the 
phylogenetic tree shown in Figure 6. Positions corresponding to K132, V178, A307, and 
L352 in the human IDH1 are highlighted. 
 
To test the function of IDH1 and the effect of different variants on IDH1 functions, 
we constructed plasmids with wildtype (WT) IDH1 and mutant IDH1 genes (pcDNA3.1-
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IDH1-A307S; pcDNA3.1-IDH1-R132H; pcDNA3.1-IDH1-V178A; and pcDNA3.1-
IDH1-L352P). We tested the enzymatic activity of the WT and each IDH1 variant by 
analysis of isocitrate dehydrogenase activity that directly tests NADPH production. We 
found that R132H and L352P mutations significant attenuated net NADPH production of 
IDH1 (Figure 5B), while A307S and V178 mutations had no significant effect. In the 
context of other R132 IDH1 studies, attenuation of net NADPH production by the R132H 
variant enzyme implies that production of 2HG in the oncogenic reaction consumes 
NADPH. These results suggest that R132H is a point mutation that disables or attenuates 
some enzymatic activity of IDH1.  
 
Figure 8. IDH1 mutations and IDH1 associated pathway analysis. 
Variant IDH1 may produce the oncometabolite 2HG that inhibits 2OG-dependent 
dioxygenases; the 2OG-dependent dioxygenases are highly sensitive to inhibition by 2HG. 
Mutations in IDH1 and 2OG dependent enzymes are mutually exclusive. The number and 
percentage of samples with mutations in each gene are shown on the left. Samples are 
displayed as columns. 
 
As previously mentioned, certain variants of IDH1 are known to produce the 
oncometabolite 2HG (Cairns & Mak, 2013; Ward et al., 2012), which showed inhibitory 
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effects on 2OG-dependent enzymes, with the histone demethylases (KDM) most sensitive 
to inhibition (Joberty et al., 2016). There are two classes of KDMs: 2OG-dependent and 
FAD-dependent. The biochemical function of both classes of KDMs is to demethylate 
specific lysine residues in histones, leading to regulation of gene expression (Labbe, 
Holowatyj, & Yang, 2013). KDMs may also regulate gene expression via demethylation 
of other residues on histones (Walport et al., 2016). Based on this information and our 
discovery of mutually exclusive mutational patterns between certain histone demethylases 
and methyl transferases, we proceeded to ask if mutations in IDH1 share a mutually 
exclusive pattern with 2OG-dependent enzymes in this lung SQCC population. We found 
that mutations in 2OG-dependent KDMs are mutually exclusive with IDH1 (Figure 8), 
suggesting that mutations in either IDH1 or the 2OG-dependent KDMs lead to a common 
inhibition of histone demethylation. The mutually exclusive mutational pattern involving 
IDH1 is statistically significant (P=0.018 based on the MEGSA (X. Hua et al., 2016) 
method). This mutual exclusion is a novel observation in lung SQCC, which has not 
previously been reported. More than 35% of AppKY patients have mutations in 2OG-
dependent protein demethylases, the vast majority of them in KDMs. Furthermore, when 
all lysine demethylases are included in the analyses, only one FAD-dependent, KDM1A, is 
found to be mutated in one case. These data suggest that IDH1 mutations may regulate 
gene expression via inhibition of 2OG-dependent KDMs. We further evaluated the 
mutations in the KDMs to see if they had functional consequences and found mutations 
possibly affecting a variety of specific regions in each of the different KDMs. The 
mutations in the KDMs are not localized to a specific region, are highly dispersive across 
each gene, and functionally affect protein-protein interactions, post-translational 
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modification sites, and metal-binding, suggesting a general loss-of-function. This loss-of-
function interpretation is further strengthened by the fact that IDH1 mutations responsible 
for the production of 2HG, which is inhibitory to KDMs (Joberty et al., 2016), are mutually 
exclusive with mutations in the above mentioned KDMs (Figure 8). The mutational 
patterns observed between IDH1 and KDMs suggest that restoring the KDM 2HG-
inhibited function in cases with certain IDH1 mutations may prevent cancer signaling 
through IDH1 (Mondesir, Willekens, Touat, & de Botton, 2016). 
2.5.7 Localization of PCMTD1 mutations  
PCMTD1 has an N-terminal canonical iso-aspartate methyl transferase (PCMT) 
domain, which in another protein has been shown to methylate iso-aspartate and aspartate 
residues on proteins including histone H4, and suggests a role in protein repair or turnover  
(Biterge, Richter, Mittler, & Schneider, 2014; McFadden & Clarke, 1982). PCTMD1’s C-
terminal domain is not well characterized, and the cellular function(s) of the gene-product 
are not known. In the AppKY dataset, mutations in PCMTD1 were always observed in the 
C-terminus coding region of the protein and never in the N-terminus region. These results 
are similar to other cancer studies including pancreatic cancer, melanoma, aggressive 
rhabdomyosarcoma and others (Figure 4B and Table 3). Therefore, the C-terminus coding 





Table 3. PCMTD1 mutations. The PCMTD1 mutations reported in the literature are in the 
C-terminal SOCS Box. PCMTD1 mutations in cancers are rarely found in the PCMT 
domain. The vast majority of mutations (except 1 case in TCGA Lung SQCC and 1 case 
in Glioblastoma) occur in the SOCS Box. 
 














22960745 Lung SQCC Yes No Yes Yes  4% 
24793135 Aggressive Rhabdomyosarcoma No No Yes No 65% 
22622578 Melanoma No Yes Yes  Yes  28% 
22610119 Prostrate No No No Yes  1% 
24816255 Gastric Carcinoma No No Yes  No 7% 
25855536 Pancreatic Cancer No Yes  Yes  No 7% 
24120142 Glioblastoma Yes No Yes No 1% 
AppKY Lung SQCC No No Yes  Yes  18% 
 
A recent report indicates that lysine methyltransferases (KMTs), KMT2A and 
KMT2D, are upregulated by gain-of-function TP53 mutations (mutations in the DNA 
binding domain) (Zhu et al., 2015). PCMTD1 is also a methyltransferase (MT). As 
mentioned earlier, isoaspartate residues of TP53 have been shown to be methylated, and 
this in turn has been shown to regulate levels of TP53 as well as its function during DNA 
damage (Lee et al., 2012). CUL5, a PCMTD1 interacting protein is recruited to target the 
TP53 protein for proteasomal degradation (Okumura, Joo-Okumura, Nakatsukasa, & 
Kamura, 2016). We explored the connections between PCMTD1 and TP53, the most 
frequently mutated gene in the AppKY dataset (69%). TP53 mutations in this cohort 
showed a strong signature for a smoking-associated mutational pattern, with frequent 
mutations in the protein regions 157-159 and 192-193 (Halvorsen et al., 2016). We also 
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found that the mutations within the smoking signature, specifically the 157-159 region 
frequently co-occur with mutations in PCMTD1.  
2.6 Conclusion 
From our analyses and other studies, there is growing evidence that numerous 
pathways converge on protein modification enzymes, including MTs and protein 
demethylases, that function via direct protein modification, and in the regulation of gene 
expression via chromatin modification. Therefore, regulation of protein MTs and 
demethylases affects the methylation status of histones and other substrates such as 
signaling proteins50. For example, mutations in PI3K/AKT signaling regulate H3K4 
methylation through KDM5A (Hamamoto, Saloura, & Nakamura, 2015), and PIK3CA and 
AKT phosphorylate KDMs and KMTs, which alters their functions and renders them 
oncogenic5 (Hamamoto et al., 2015; K. Xu et al., 2012). Thus, these methyltransferases 
and demethylases may be promising targets in cancer therapy. 
The observation of a smoking-associated mutational signature in TP53 is not 
surprising (Schoenberg, Huang, Seshadri, & Tucker, 2015) given the high rate of smoking 
in AppKY, and this signature appears to frequently co-occur with mutations in PCMTD1. 
We hypothesize that PCMTD1 could function as a regulator of TP53, although further 
study will be needed to examine this hypothesis. In the AppKY population, concentrations 
of arsenic, chromium and nickel are higher than the US national levels (Johnson et al., 
2011). The toxicity of carcinogenic metals has been shown to be mediated by altering 
histone methylation via 2OG-dependent enzymes (Arita et al., 2012; Chervona, Arita, & 
Costa, 2012). In addition to the known link to tobacco exposure, we hypothesize that 
environmental exposures relevant to AppKY may be contributing to the development of 
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this (R)-2-hydoxyglutarate-specific cancer mechanism in our cohort. This could help 
explain the IDH1 and 2OG-dependent KDMs mutually exclusive pattern seen only in the 
AppKY cohort.  
This study is the first characterization of the genomic alterations in lung SQCC 
from AppKY residents. Our data shares several findings with the TCGA, namely high rates 
of TP53, NOTCH1, PTEN and PI3KCA, the complexity of genomic patterns, and well-
recognized pathways upregulated in SQCC lung cancer. However, the AppKY SQCC has 
a specific genetic signature characterized by an increased number of IDH1 and PCMTD1 
mutations, as compared to the TCGA. The findings in this study have important 
mechanistic implications for how SQCC lung cancers develop in AppKY residents and 
provide insights into treatment. The 10% potentially actionable mutations/SCNAs 
observed in our AppKY cohort (based on FDA-approved drugs) coupled with 65% of 
subjects with high or intermediate mutation burden indicates that a majority of these 
patients have potential molecular targets for treatment including ERBB2 amplification with 
FDA approved monoclonal antibodies and tyrosine kinase inhibitors; PDGFRA, and TSC2 
where targeted agents are approved in other tumor types; as well as other mutations with 
targeted therapies under active investigation (HRAS, KRAS, PTEN, NOTCH1, NF1, BRAF). 
The current study adds to the body of literature that supports drug development based on 
mutations in lung SQCC and highlights genomic population differences that are relevant. 
By utilizing therapies specific to actionable mutations that are common in our AppKY 
population, we can provide a more personalized approach through directed drug discovery 




CHAPTER 3. MESCAN: A Powerful Statistical Framework for Genome-Scale Mutual 
Exclusivity Analysis of Cancer Mutations 
3.1 Introduction 
Cancer arises from somatically acquired genetic and epigenetic alterations. While 
large consortia like TCGA and ICGC have profiled genomic somatic mutations of 
thousands of tumor samples from various cancer types based on whole-genome/-exome 
sequencing, meaningful mechanistic interpretation of these gene variation results are still 
very limited. One basic yet challenging task is to distinguish driver mutations, which are 
causally implicated in cancer development, from passenger mutations, which occur 
randomly with neutral effect. Despite a few exceptions, most driver mutations occur in 
only a small fraction of tumor samples (Tamborero et al., 2013). Therefore, identifying 
these low recurrent driver mutations that are buried among a vast pool of passenger 
mutations is challenging.  Tremendous efforts have been spent on identifying driver 
mutations ((L. Ding et al., 2018); ICGC/TCGA Pan-Cancer Analysis of Whole Genomes 
Consortium, 2020). It has been suggested that assessing mutations in a set of related genes 
may enhance the power of the detection, since genes act together in various biological 
(regulatory, signaling, and metabolic) pathways (Leiserson, Blokh, Sharan, & Raphael, 
2013; M. D. M. Leiserson, H.-T. Wu, F. Vandin, & B. J. Raphael, 2015; Szczurek & 
Beerenwinkel, 2014; Vandin, Upfal, & Raphael, 2012). Mutations associated with genes 
within a pathway often show a mutually exclusive pattern across a cohort of patients, 
meaning that each patient carries just one mutation in the pathway, which is often sufficient 
to perturb the function of that pathway. Although the mutation rate for each gene in the 
pathway is often low, the mutually exclusive mutations among genes in the pathway 
provide a stronger combined signal that is easier to detect. This is due to the increased 
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mutation rate by considering the set of genes as a whole as well as the mutually exclusive 
pattern across genes that provides an additional signal for detection. 
Several bioinformatics methods have been developed for de novo discovery of 
mutually exclusive gene sets (Constantinescu, Szczurek, Mohammadi, Rahnenfuhrer, & 
Beerenwinkel, 2016; Li Ding et al., 2018; Xing Hua et al., 2016; Y.-A. Kim, S. Madan, & 
T. M. Przytycka, 2017; Leiserson et al., 2013; M. D. M. Leiserson, M. A. Reyna, & B. J. 
Raphael, 2016; M. D. M. Leiserson et al., 2015; Mina et al., 2017; Szczurek & 
Beerenwinkel, 2014; Vandin et al., 2012). However, there are still three major challenges. 
Firstly, the heterogeneity in background (or passenger) mutation rate needs to be adjusted. 
Lawrence et.al (Michael S. Lawrence et al., 2013) demonstrated large variation in the 
background mutation rate across genes and across patients of the same cancer type from 
TCGA data. Adjusting for a patient- and gene-specific background mutation rate has been 
shown as the key to reducing artifactual findings and improving the identification of driver 
genes (Korthauer & Kendziorski, 2015; Michael S. Lawrence et al., 2013; Youn & Simon, 
2011) . This is also true for dN/dS-style tests, where dS represents a proxy for background 
mutation rate (Nik-Zainal et al., 2016; Zhao et al., 2019). The heterogeneity in the 
background mutation rate can also affect identification of mutually exclusive mutational 
patterns, because spurious patterns are more likely to occur in genes and patients with high 
background mutation rates. However, only a few mutual exclusivity analysis methods have 
taken into account the heterogeneity in the background mutation rate, and adjustment 
approaches are limited. Hua et al. (X. Hua et al., 2016) used a likelihood-based approach 
to directly adjust for the background mutation rate. However, the method is based on the 
assumption that the relative mutation frequencies of genes in a mutually exclusive gene set 
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are proportional to the background mutation frequencies of those genes. It also assumed 
the same background mutation rate of a gene across patients. A few other methods (Y. A. 
Kim, S. Madan, & T. M. Przytycka, 2017; M. D. Leiserson, M. A. Reyna, & B. J. Raphael, 
2016; M. D. Leiserson, H. T. Wu, F. Vandin, & B. J. Raphael, 2015) used a conditional 
technique to indirectly adjust for the mutation rate heterogeneity. These methods used 
either permutation or a hypergeometric distribution method to make inferences by 
conditioning on the observed mutation frequencies of genes and patients. However, the 
conditional technique was unable to distinguish whether the observed mutation frequencies 
were due to random background noise or true signals that drive cancer development. 
Secondly, as pointed out by Leiserson et al. (M. D. Leiserson et al., 2015), a gene 
with a very high mutation rate plus a few other genes with very low mutation rates may 
show a mutually exclusive mutational pattern by random chance. The highly mutated gene, 
e.g. TP53 in several cancer types, could be a driver gene by itself. But other genes in this 
spurious mutually exclusive set may not be drivers and may be biologically unrelated to 
the highly mutated gene. Therefore, such an unbalanced pattern, which is dominated by the 
highly mutated gene, is less of interest as compared to a more balanced pattern, where each 
gene in the gene set has a non-negligible contribution to the overall pattern. Note that 
adjusting for the background mutation rate does not solve this problem. The highly mutated 
gene could be a driver whose mutation rate is much higher than the background so that the 
pattern would still be significant even after the background mutation rate adjustment. Many 
bioinformatics methods do not distinguish unbalanced and more balanced patterns, and 
therefore can lead to spurious results. Although a conditional method (M. D. Leiserson et 
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al., 2015) has been proposed to favor more balanced patterns, its power could still be 
affected by the presence of a highly mutated gene based on our simulations. 
Thirdly, computational efficiency is a major hurdle for genome-scale screening of 
mutual exclusive gene sets. Most methods (Constantinescu et al., 2016; X. Hua et al., 2016; 
Y. A. Kim et al., 2017; M. D. Leiserson et al., 2016; M. D. Leiserson et al., 2015; Szczurek 
& Beerenwinkel, 2014) are based on statistical tests to examine mutual exclusivity of gene 
sets. However, current statistical tests have high computational burden because they 
involve computationally intensive statistical modeling and/or require permutation to 
calculate p-values. Furthermore, the computational burden increases dramatically as the 
size of the candidate gene set increases. A few methods have been proposed to reduce this 
computational burden. WExT (M. D. Leiserson et al., 2016) used a saddlepoint algorithm 
to approximate the permutation test, but its computational efficiency was not sufficiently 
high. WeSME (Y. A. Kim et al., 2017) proposed a weighted sampling algorithm instead of 
permutation, but the algorithm was limited to examining two genes at a time. As a 
compromise, most methods only focused on genes with relatively high mutation rates 
and/or known to be cancer drivers. The number of genes they considered was typically less 
than 1000, or even less than 100, which limited their ability to perform genome-scale 
screening. 
Due to these major hurdles, current mutual exclusivity analysis methods have 
limited ability of analyzing the whole genome to identify novel driver genes, especially 
those with low mutation frequencies. In this project, we explore methods for removing 
those hurdles so as to unleash the power of mutual exclusivity analysis for genome-wide 
screening of driver gene mutations. To address the challenges mentioned in the cancer 
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driver mutation discovery, MEScan is developed based on a statistical test to de novo 
screen mutually exclusive patterns at the genome scale. The framework has the following 
key component: 1) the test statistic directly quantifies the discrepancy between the 
observed level of mutual exclusivity and the expected value due to the background, where 
a patient-specific and gene-specific background mutation rate is taken into account.; 2) it 
incorporates a gene-specific weight to adjust for gene mutation frequencies, favoring more 
balanced rather than unbalanced patterns; 3) test statistic only involves simple algebra, and 
thus is very fast to calculate. Equipped with this very fast test, MEScan implement a 
Markov chain Monte Carlo (MCMC) algorithm to efficiently scan for mutually exclusive 
gene sets at the genomic scale, a false discovery rate (FDR) adjustment procedure to control 
false positives, and a summarization procedure to select high-confidence findings. We 
demonstrate our test statistics outperforms several existing methods based on simulation 
studies. And our algorithm has been applied to TCGA data for genome-scale screening of 
mutually exclusive gene sets. 
3.2 MEScan Framework 
The overview of the MEScan framework is in Figure 9. Overview of the MEScan 
framework.. We propose a test statistic, TG, to examine whether a candidate gene set G 
pertains to a mutually exclusive mutational pattern. The TG  quantifies the difference 
between the observed potential of mutual exclusivity in G with its expected value due to 
background noise. A TG larger score indicates that the gene set is more likely to be mutually 
exclusive. As the background mutation rate varies across patients and genes, the TG 
incorporates a patient- and gene-specific background mutation rate in the calculation to 
adjust for the background noise. In addition, TG includes a gene-specific weight to down-
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weigh genes with very high mutation rates, which could lead to spurious unbalanced 
mutually exclusive patterns. As illustrated in the figure, the candidate gene set G =
(g2, g4, g5) appears to show a mutually exclusive mutational pattern. However, most of the 
mutations are from gene g2  while the other two genes, g4  and g5  , have very few 
mutations. The apparent mutually exclusive pattern is highly unbalanced and dominated 
by g2. To balance the impact of each individual gene on the overall pattern, our TG statistic 
includes a gene-specific weight, which is inversely correlated with the gene's mutation rate, 
to reduce the impact of g2. Furthermore, TG is very fast to calculate, which is critical for 




Figure 9. Overview of the MEScan framework.A key component of MEScan is a fast and 
powerful statistical test, TG, for assessing mutual exclusivity of a candidate gene set. This 
test accounts for a patient- and gene-specific background mutation rate (for illustration, 
darker blue indicates higher and lighter blue indicates lower background mutation rate). 
By using a gene-specific weight, the test also balances the impact of each gene on the 
overall significance of the gene set. Based on this test, our genome-scale screening follows 
a multi-step procedure. Starting from the observed mutation data matrix, an MCMC 
algorithm is used to screen across candidate gene sets, where the probability of a gene set 
being sampled is proportional to the TG score of that set. Next, significant gene sets are 
identified with the control of the FDR. Finally, high-confidence gene sets are selected 
based on the criteria that all subsets of them are also significant and they do not have 
substantial overlaps. 
Building upon this test, we use a multi-step procedure for genome-scale screening 
of mutually exclusive gene sets. Firstly, we use an MCMC algorithm to efficiently identify 
potential mutually exclusive gene sets at the genomic scale. According to the COSMIC 
database (Forbes et al., 2015), somatic mutations have been identified in over 20,000 genes. 
Given the vast number of candidate genes and numerous combinations of genes to form 
gene sets, examining all the possible gene sets is impractical. Therefore, for each size of 
candidate gene set, we construct a Markov chain such that the probability of sampling each 
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gene set is proportional to the TG score of that gene set. This method allows for more 
efficient screening and puts more focus on the gene sets that are more likely to be mutually 
exclusive. Secondly, we identify significant mutually exclusive gene sets by implementing 
an FDR control method. Finally, we select high-confidence mutually exclusive gene sets 
by investigating significant gene sets across different sizes. Roughly speaking, a high-
confidence mutually exclusive gene set satisfies that 1) itself and all its subsets are 
significant gene sets; and 2) it does not have substantial overlap with another high-
confidence mutually exclusive gene set. We expect these high-confidence mutually 
exclusive gene sets, which are strongly supported by the data and distinct from each other, 
are of most interest for further biological interpretation and investigation. 
3.3 Testing mutual exclusivity of a single gene set 
We have developed a new statistical test to examine the presence or absence of a 
mutually exclusive pattern for a gene set G based on mutation data from a cohort of n 
patients, while adjusting for patient- and gene-specific background mutation rate as well 
as the impact of highly mutated genes. Our test statistic quantifies the observed potential 
of mutual exclusivity beyond what is expected due to random background for each gene 
and patient, and then takes a summation across genes and patients. To favor more balanced 
patterns, each gene's contribution to the overall test is weighted by a factor inversely 
correlated with its mutation rate. 
Let 𝑈𝑈𝑖𝑖𝑖𝑖 take value 1 or 0 to indicate whether the ith patient satisfies the mutually 




where Yig takes value 1 or 0 to indicate if gene g is mutated in patient i. Under the 
null hypothesis of no mutually exclusive pattern, the expectation of Uig is 
E�𝑈𝑈𝑖𝑖𝑖𝑖� = P�𝑈𝑈𝑖𝑖𝑖𝑖 = 1� = η𝑖𝑖𝑖𝑖 � (1 − η𝑖𝑖𝑖𝑖)
𝑖𝑖≠𝑖𝑖,𝑖𝑖∈𝐺𝐺
≡ θ𝑖𝑖𝑖𝑖 
where ηig is the background mutation rate for gene 𝑔𝑔 in patient 𝑖𝑖 calculated based 
on the MADGiC (Korthauer & Kendziorski, 2015) method. MADGiC considers a 
multiplicative model that quantifies the patient- and gene-specific background mutation 
rate by a product of parameters representing a number of factors that are known to affect 
the mutation rate. Those factors include patient-specific mutation rate, mutation type and 
dinucleotide context (the specific nucleotide change of the mutation and whether the 
mutation occurs in CpG dinucleotides), replication timing of the region and expression 
level of the gene. The empirical Bayes method is used to estimate the patient-specific 
mutation rate parameter, and the method of moments is used to estimate other parameters. 
We quantify the contribution of gene 𝑔𝑔  in patient 𝑖𝑖  to the mutually exclusive 
pattern by Zig = Uig�Uig − θig�,  which calculates the difference between the observed 
value of Uig and its expected value under the null hypothesis. By standardizing Zig and 
taking a weighted sum across genes in G, we obtain the following statistic to quantify the 
evidence of mutual exclusivity in the 𝑖𝑖th patient 
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where Var�Zig� = θig�1 − θig�
3
 is the variance of Zig, and λ is a small constant to 
mitigate the impact of extremely small θigvalues. Following the suggestion of (Tusher, 
Tibshirani, & Chu, 2001), we set λ to be the 5th percentile of all �θig's, where �θig is 
approximately the standard deviation of Zig because θig is usually much smaller than 1 so 
that �θig�1 − θig�
3 ≈ �θig. 
It is important to note that in Equation (1), we include a gene-specific weight, wg, 
to adjust for the difference in mutation rate of genes in G. Specifically,  
wg =
1/∑ Uigni=1
∑ [1/∑ Uisni=1 ]s∈G
. 
As wg is inversely correlated with the mutation rate of gene g, it down-weighs the 
impact of highly mutated genes, such as TP53, to the overall statistic, and therefore makes 
the statistic favor balanced patterns. The wg  removes the confounding effect of the 
difference in genes’ mutation rates by standardizing the statistic to a balanced pseudo-
population, where the number of subjects having mutations in 𝑔𝑔 but not other genes in =-
 G is the same for each g ∈ G. It is analogous to the inverse probability weighting in survey 
sampling (Little, 1991; Pfeffermann, 1996). 
Finally, we take the sum of 𝑇𝑇𝑖𝑖 over all patients and standardize it to obtain our test 
statistic, 𝑇𝑇𝐺𝐺, for mutual exclusivity of gene set 𝐺𝐺:  
 TG =



















The 𝑇𝑇𝐺𝐺 can be calculated very quickly because the formula only involves simple 
algebra. This high computational efficiency is key to enable screening over a vast number 
of candidate gene sets. 
3.4 Genome-wide screening 
The efficiency test TG makes it possible to perform genomic scale screening for 
mutually exclusive gene sets from thousands of genes. However, due to the vast number 
of candidate gene sets, it is still impractical to perform a mutual exclusivity test 
exhaustively on each of those gene sets. Therefore, we consider an MCMC method to 
screen candidate gene sets more efficiently and prioritize gene sets that are more likely to 
pertain the mutually exclusive pattern. We define a probability distribution on candidate 
gene sets satisfying that the probability of a candidate gene set is proportional to its TG 
score. A Markov chain is then constructed to have that probability distribution as its 
equilibrium distribution. Therefore, the MCMC algorithm favors sampling gene sets with 
large TG scores, which are more likely to be mutually exclusive sets. A similar approach 
was used in (M. D. M. Leiserson et al., 2015). 
54 
 
In the implementation, we consider a separate MCMC for each size of gene sets. 
For each MCMC, we use the following Metropolis-Hastings algorithm to obtain Monte 
Carlo samples. For a gene set G, we define NB(G) as a collection of its neighborhood gene 
sets who contain the same number of genes as 𝐺𝐺 and differ from 𝐺𝐺 by only one gene. We 
require that a gene set can only transit to its neighborhood gene sets. Specifically, at each 
MCMC iteration, the proposed state 𝐺𝐺' given the current state 𝐺𝐺 is a random sample from 
𝑁𝑁𝑁𝑁(𝐺𝐺). The Metropolis acceptance probability for 𝐺𝐺' is  






where τ is a tuning parameter to control the acceptance rate to be around 30%. 
3.5 Determining a cutoff value to control the FDR 
We identify significantly mutually exclusive gene sets by controlling the FDR<0.05 
based on the local fdr method from a previous publication (Efron, 2004b). The local fdr 
method considers the observed distribution of 𝑇𝑇𝐺𝐺  as a mixture of null and non-null 
distributions. It empirically estimates the null and non-null distributions for possibly non-
independent test statistics of large-scale simultaneous hypothesis testing. The FDR is then 
calculated based on the empirical null and non-null distributions.  A cutoff value of 𝑇𝑇𝐺𝐺 
corresponding to FDR < 0.05 is determined so that gene sets with 𝑇𝑇𝐺𝐺  scores larger than 
the cutoff value are considered as significantly mutually exclusive.  The cutoff value is 
determined for each size of gene sets separately. Note that the original method in (Efron, 
2004b) requires using the 𝑇𝑇𝐺𝐺 's of all candidate gene sets to estimate the empirical null and 
non-null distributions and determine the 𝑇𝑇𝐺𝐺  cutoff value, which is computationally 
intractable for our situation. As those gene sets are randomly selected, they are likely to 
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represent the distribution of  TG in all candidate gene sets. Therefore, instead of using all 
candidate gene sets, we randomly sample 107  gene sets to estimate the empirical null 
distribution and determine the TG cutoff value for each size of gene sets. Based on real data 
analysis, as shown in Figure 14. TG cutoff value estimation. For each size of candidate gene 
sets, the cutoff value of TG for controling FDR < 0.05 was estimated by sampling 107 (red 
square) or 108 (blue diamond) candidate gene sets., sampling 107 gene sets are sufficient 
to obtain stable cutoff values. 
3.6 Identifying high-confidence mutually exclusive gene sets 
By applying the TG cutoff value as described in the last subsection, we can identify 
a number of significant mutually exclusive gene sets with FDR < 0.05 for each size of gene 
sets. Let ℳ be a collection of the significant gene sets across all sizes.  
Based on our experience, there can be a large number of gene sets in ℳ and many 
of those gene sets overlap with each other. To promote more robust and focused inferences, 
we further define high-confidence mutually exclusive gene sets, satisfying that 1) all 
subsets are also significantly mutually exclusive; and 2) different gene sets do not have 
substantial overlaps. A two-step procedure is used to select high-confidence mutually 
exclusive gene sets. The first step identifies all maximal cliques in ℳ. A clique is defined 
as a gene set (size ≥ 3) such that itself and all of its subsets (size ≥ 2) are all in ℳ. A 
maximal clique is a clique that cannot be expanded by including any additional gene. These 
maximal cliques are likely to be real mutually exclusive sets because they are validated by 
all their subsets. Note that we do not consider gene sets of size 2 as cliques because they 
do not have subsets to validate. The second step removes largely overlapped maximal 
cliques of the same size. For maximal cliques of size > 3, if the number of overlapped genes 
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between two maximal cliques of the same size is > 50% of the size, we remove one of them 
with a lower TG score. For maximal cliques of size = 3, because the size is too small to 
define meaningful overlaps, we simply select the top 100 maximal cliques with the largest -
TG scores. After the two-step procedure, the remaining maximal cliques are considered as 
high-confidence mutually exclusive gene sets. 
3.7 Results 
3.7.1 Simulation studies 
We performed simulation studies to evaluate the performance of MEScan and 
compared to the following five existing methods: MEGSA, Dendrix (version 0.3), TiMEx 
(version 0.99.0), WExT (weighted-row exclusivity test, version 1.3.0) and CoMEt. For 
CoMEt, we used the WExT row-exclusivity test implementation as suggested by the paper 
(M. D. Leiserson et al., 2016). To mimic a real-world situation, the simulated datasets were 
generated based on the TCGA ovarian cancer dataset described in the Real data analysis 
subsection.  
3.7.1.1 Simulation studies to evaluate methods' performance in identifying subsets of a 
true mutually exclusive gene set without the presence of highly mutated genes 
As the goal of the analysis is to identify truly mutually exclusive mutation patterns 
while avoiding spurious patterns, the following simulation studies were conducted to 
evaluate and compare each method's performance in ranking candidate gene sets. We 
randomly selected 200 patients and 3 genes from TCGA ovarian cancer dataset and 
artificially added a mutually exclusive mutational pattern on 10%, 20%, 30%, or 40% of 
patients, which was referred to as the coverage. We considered two different mutually 
exclusive mutational patterns, one with a 1:1:1 ratio of mutation frequencies for the three 
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genes (equal number of mutations in each gene) and the other with a 3:2:1 ratio of mutation 
frequencies. We additionally included 17 other genes, each has at least 5 mutations in the 
TCGA ovarian cancer dataset, as “noisy” genes without any mutually exclusive pattern. 
We considered two different approaches to select those genes. One approach was to 
randomly select 17 genes from the real data. The other was to intentionally include TP53, 
which had a high mutation frequency of 94.6%, and randomly select the other 16 genes. 
This second approach aimed to assess each method's performance in the presence of a 
highly mutated driver gene but not part of the mutually exclusive pattern, where such a 
gene could yield spurious unbalanced mutually exclusive patterns by random chance.  
We first evaluated methods' performance in identifying the true 3-gene mutually 
exclusive gene set. Under each scenario, we applied each method (except for TiMEx) to 
all candidate gene sets of size 3 and identified the top-ranked gene set. Here, the candidate 
gene sets were ranked based on the TG score for MEScan, the weight W for Dendrix, the 
p-value for CoMEt, WExT and TiMEx, and the likelihood for MEGSA. Note that because 
TiMEx is computationally intensive, we only applied it to a smaller subset of candidate 
gene sets, i.e., the union of top 10 gene sets ranked by each of the other methods and the 
gene set with the true mutual exclusive pattern, which may bias the result in favor of this 
method. Our simulations were replicated 100 times and the frequency that the top-ranked 
gene set was the gene set containing the true mutually exclusive mutation pattern we 




Figure 10. Comparison of power for identifying a true mutually exclusive gene set based 
on simulations.  Each simulated dataset contained 20 genes, including 3 genes with a true 
mutually exclusive mutational pattern and the other 17 genes without any pattern. 
Simulations were replicated 100 times and the power was calculated as the frequency that 
the top-ranked gene set was the 3-gene set with the true mutually exclusive mutational 
pattern. Four scenarios were considered. A) The ratio of mutation frequencies was 1:1:1 
for the 3 genes and the other 17 genes did not include a highly mutated gene; B) the ratio 
of mutation frequencies was 3:2:1 for the 3 genes and the other 17 genes did not include a 
highly mutated gene; C) the ratio of mutation frequencies was 1:1:1 for the 3 genes and the 
other 17 genes included a highly mutated gene; and D) the ratio of mutation frequencies 
was 3:2:1 for the 3 genes and the other 17 genes included a highly mutated gene. 
 
Figure 10 shows the simulation results. In all scenarios, MEScan had the highest 
power compared to other methods, especially when the coverage was low. For example, 
when a true mutually exclusive pattern with equal number of mutations in each of the three 
genes was presented in 10% of patients, MEScan was able to achieve 80% power (Figure 
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10A). In contrast, all other methods had power less than 25%. This is likely due to the 
adjustment of the background mutation rate by MEScan, which provides a better detection 
of true patterns against spurious patterns coming from random noise. 
3.7.1.2 Simulation studies to evaluate methods' performance in identifying subsets of a 
true mutually exclusive gene set with the presence of highly mutated genes 
We next assessed the impact of a highly mutated noisy gene (TP53) that was not 
part of the true mutually exclusive pattern. Figure 11. Comparison of power for identifying 
subsets of a true mutually exclusive gene set based on simulations. Each simulated dataset 
contained 20 genes, including 3 genes with a true mutually exclusive mutational pattern 
and the other 17 genes without any pattern. Simulations were replicated 100 times and the 
power was calculated as the frequency that the top-ranked 2-gene set was a subset of the 
true 3-gene mutually exclusive mutational pattern. Four scenarios were considered. A) The 
ratio of mutation frequencies was 1:1:1 for the 3 genes and the other 17 genes did not 
include a highly mutated gene; B) the ratio of mutation frequencies was 3:2:1 for the 3 
genes and the other 17 genes did not include a highly mutated gene; C) the ratio of mutation 
frequencies was 1:1:1 for the 3 genes and the other 17 genes included a highly mutated 
gene; and D) the ratio of mutation frequencies was 3:2:1 for the 3 genes and the other 17 
genes included a highly mutated gene. compares the power of each method in the absence 
(top panels) vs. presence (bottom panels) of TP53. MEScan was able to maintain the power 
after the addition of the highly mutated gene, indicating that it was robust to such a gene 
that could cause spurious unbalanced patterns by random chance. In contrast, the power of 
all other methods decreased. Dendrix did not have any power even when the coverage 
increased, which is as expected, because it was sensitive to unbalanced spurious patterns. 
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In fact, the top-ranked gene set from Dendrix was always a set containing TP53. CoMEt, 
which used a conditional method to reduce the bias towards unbalanced patterns, also had 
substantial decrease in power. Therefore, the conditional method appeared not adequately 




Figure 11. Comparison of power for identifying subsets of a true mutually exclusive gene 
set based on simulations. Each simulated dataset contained 20 genes, including 3 genes 
with a true mutually exclusive mutational pattern and the other 17 genes without any 
pattern. Simulations were replicated 100 times and the power was calculated as the 
frequency that the top-ranked 2-gene set was a subset of the true 3-gene mutually exclusive 
mutational pattern. Four scenarios were considered. A) The ratio of mutation frequencies 
was 1:1:1 for the 3 genes and the other 17 genes did not include a highly mutated gene; B) 
the ratio of mutation frequencies was 3:2:1 for the 3 genes and the other 17 genes did not 
include a highly mutated gene; C) the ratio of mutation frequencies was 1:1:1 for the 3 
genes and the other 17 genes included a highly mutated gene; and D) the ratio of mutation 
frequencies was 3:2:1 for the 3 genes and the other 17 genes included a highly mutated 
gene. 
3.7.1.3 Simulation studies to evaluate methods' performance in identifying the true 
mutually exclusive gene set across candidate gene sets of different sizes 
We adapted the same simulation scenarios and  applied each methods to all 
candidate gene sets of sizes from 2 to 6. We calculated the fraction of simulations that the 
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top-ranked gene set was exactly the true 3-gene mutually exclusive set, is a subset of the 
true set, contains the true set, or otherwise. Compared to other methods, MEScan yielded 
the highest fraction of simulations with the top-ranked gene set being the true mutually 
exclusive set when the coverage was low. It was also robust to the presence of a highly 
mutated noisy gene. Figure 12 Simulation results for applying MEScan, MEGSA, Dendrix, 
WExT and CoMEt across different sizes (2 to 6) of candidate gene sets. Bar graphs show 
the fractions of simulations that the top-ranked gene set is exactly the true 3-gene mutually 
exclusive set (green), is a subset of the true set (blue), contains the true set (yellow), or 
otherwise (red). Each simulated dataset contained 20 genes, including 3 genes with a true 
mutually exclusive mutational pattern and the other 17 genes without any pattern. 
Simulations were replicated 100 times. Four scenarios were considered. A) The ratio of 
mutation frequencies was 1:1:1 for the 3 genes and the other 17 genes did not include a 
highly mutated gene; B)  the ratio of mutation frequencies was 3:2:1 for the 3 genes and 
the other 17 genes did not include a highly mutated gene; C) the ratio of mutation 
frequencies was 1:1:1 for the 3 genes and the other 17 genes included a highly mutated 
gene; and D) the ratio of mutation frequencies was 3:2:1 for the 3 genes and the other 17 
genes included a highly mutated gene.shows the results for all the methods. For the 
scenarios that the ratio of mutation frequencies of the three genes in the true set was 1:1:1, 
MEScan had the largest fraction of simulations that ranked the true 3-gene set to the top 
among all methods when the coverage was 0.1 to 0.3, while CoMEt had the largest fraction 
when the coverage was 0.4. For the scenarios that the ratio of mutation frequencies of the 
three genes in the true set was 3:2:1, MEScan more frequently ranked a 2-gene subset of 
the true set to the top. This is as expected because one of the three genes had a low mutation 
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frequency, making it more dicult to be identied. For the purpose of identifying driver genes, 
MEScan was conservative since all genes in the top-ranked set were part of the true signal. 
In contrast, other methods tended to more frequently rank larger gene sets, containing some 
noisy genes in addition to genes in the true set, to the top, which was anti-conservative. In 
addition, MEScan was still able to identify the true 3-gene set in a fraction of simulations 
under low coverage situation (coverage = 0.1 or 0.2), where other methods were unable to 
identify the true set. Furthermore, MEScan's performance remained the same in the absence 
or presence of a highly mutated noisy gene, suggesting that MEScan was robust to the 
presence of such a gene. In contrast, the top-ranked gene sets based on Dendrix, WExT 
and CoMEt were almost always neither the true set nor a superset of the true set in the 






Figure 12 Simulation results for applying MEScan, MEGSA, Dendrix, WExT and CoMEt 
across different sizes (2 to 6) of candidate gene sets. Bar graphs show the fractions of 
simulations that the top-ranked gene set is exactly the true 3-gene mutually exclusive set 
(green), is a subset of the true set (blue), contains the true set (yellow), or otherwise (red). 
Each simulated dataset contained 20 genes, including 3 genes with a true mutually 
exclusive mutational pattern and the other 17 genes without any pattern. Simulations were 
replicated 100 times. Four scenarios were considered. A) The ratio of mutation frequencies 
was 1:1:1 for the 3 genes and the other 17 genes did not include a highly mutated gene; B)  
the ratio of mutation frequencies was 3:2:1 for the 3 genes and the other 17 genes did not 
include a highly mutated gene; C) the ratio of mutation frequencies was 1:1:1 for the 3 
genes and the other 17 genes included a highly mutated gene; and D) the ratio of mutation 
frequencies was 3:2:1 for the 3 genes and the other 17 genes included a highly mutated 
gene. 
3.7.1.4 Simulation studies to evaluate methods' performance in controlling the false 
discovery rate (FDR) 
We further evaluated the FDR control of our method. In the absence of a highly 
mutated noisy gene, the observed FDR was around the nominal FDR. In the presence of a 
highly mutated noisy gene, the observed FDR was smaller than thee nominal FDR. These 
results suggests that our method was able to control the FDR. We considered the same four 
simulation scenarios as described in the main text. We investigated all candidate gene sets 
of size 3, and calculated the observed FDR corresponding to the nominal FDR of 0.01, 
0.05, 0.1, and 0.2. Note that the null hypothesis for a mutual exclusivity test is that the three 
genes do not have any mutually exclusive pattern. The alternative hypothesis is that there 
is a mutually exclusive pattern, which includes both the case of a full mutually exclusive 
pattern among all the three genes and the case of a partial mutually exclusive pattern in two 
of the three genes. Both cases are considered as true positives in our calculation. In our 
simulations, the full and partial patterns are overlapping, and thus correlated with each 
other. Figure 12 Simulation results for applying MEScan, MEGSA, Dendrix, WExT and 
CoMEt across different sizes (2 to 6) of candidate gene sets. compares the nominal FDR 
versus the observed FDR. In the absence of a highly mutated noisy gene, the observed FDR 
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was around the nominal FDR. In the presence of a highly mutated noisy gene, the observed 
FDR was smaller than thee nominal FDR. These results suggests that our method was able 
to control the FDR.  
 
Figure 13 Evaluation of the FDR control based on simulations.  Each simulated dataset 
contained 20 genes, including 3 genes with a true mutually exclusive mutational pattern 
having a coverage of 0.2 and the other 17 genes without any pattern. Simulations were 
replicated 100 times. Four scenarios were considered. A) The ratio of mutation frequencies 
was 1:1:1 for the 3 genes and the other 17 genes did not include a highly mutated gene; B)  
the ratio of mutation frequencies was 3:2:1 for the 3 genes and the other 17 genes did not 
include a highly mutated gene; C) the ratio of mutation frequencies was 1:1:1 for the 3 
genes and the other 17 genes included a highly mutated gene; and D) the ratio of mutation 





Our proposed identification of high-confidence mutually exclusive gene sets 
provides a way to further select full patterns out of partial patterns. This is because a high-
confidence mutually exclusive gene set requires that all its subsets are also significantly 
mutually exclusive. For a gene set containing a partial pattern, some of its subsets may not 
contain >1 genes from the mutually exclusive pattern, and thus are likely to be non-
significant. Therefore, the identification of high-confidence mutually exclusive gene sets 
can potentially filter out those gene sets with partial patterns. To demonstrate this, we 
performed high-confidence mutually exclusive gene sets identification based on the 
simulated datasets. In all simulations, the true 3-gene set always remained in the high-
confidence sets as long as the high-confidence sets was non-empty.  For balanced pattern 
situations (scenarios A and C), in 44% to 50% of simulations, the high-confidence sets 
only  contains a single gene set, which is the true set, suggesting that our method was able 
to filter out gene sets with partial pattern. For less balanced pattern situations (scenarios B 
and D), our method was able to identify the single true gene set in 23% to 24% of 
simulations. The reduced percentage compared to balanced pattern situations was due to 
the fact that there was a gene with low coverage in the true set under less balanced 
situations, which was harder to detect. It should also be pointed out that in 20% to 50% of 
simulations, the resulting high-confidence set was empty, suggesting that the selection of 
high-confidence set was very stringent so that the true set could sometimes be filtered out. 
To sum up, the identification of high-confidence mutually exclusive gene sets appears to 




3.7.2 Time cost comparison 
Computational time is very critical for a mutual exclusivity test due to the vast 
number of candidate gene sets needing to be examined. We compared the computational 
time of MEScan, MEGSA, Dendrix, WExT and CoMEt for assessing 1000 candidate gene 
sets for each of the size 3 to 7 based on 200 patients randomly selected from the TCGA 
ovarian cancer dataset. Note that TiMEx was not included in the comparison, because it 
was substantially slower than other methods. Table 4 presents the running time of each 
method. MEScan was the fastest method. The only other method that was on the same scale 
as MEScan is Dendrix. However, as pointed out by Leiserson et al. (2015)  (M. D. 
Leiserson et al., 2015) and also observed in our simulations, Dendrix did not adjust for the 
impact of highly mutated genes, and therefore could lead to spurious results. Apart from 
Dendrix, MEScan was at least two orders of magnitude faster than the rest three methods. 
For example, it took MEScan only 0.017 seconds to analyze 1000 gene sets of size 3, while 
the other three methods took more than 8 seconds. In addition, MEScan only had a less 
than 2-fold increase in computational time as the size of gene set increased from 3 to 7. In 
contrast, CoMEt and WExT had a 10-fold increase in computational time. Therefore, 
MEScan provides a very fast and robust test that is instrumental for genome-scale screening 
of mutually exclusive gene sets. 
Table 4. Comparison of computational time. The reported computational time (in seconds) 
was for analyzing 1000 gene sets of a given size. 
Size of gene 
set  MEScan MEGSA Dendrix WExT CoMEt 
3 0.017 14.604 0.052 8.807 8.488 
4 0.021 18.166 0.056 12.791 12.701 
5 0.022 26.26 0.06 31.575 23.611 
6 0.023 37.285 0.061 50.402 46.922 




3.7.3 Choosing cutoff values of 𝑇𝑇𝐺𝐺 to control FDR 
In genome-scale screening, a cutoff value of TG  is determined based on the 
empirical distribution of TG (Efron, 2004a) to control for the FDR for each size of gene 
sets. As it is impractical to obtain TG for all candidate gene sets, we randomly selected a 
fraction of gene sets to estimate the empirical distribution of TG for each gene set size and 
then determine the cutoff value. To determine how large the fraction is needed to obtain 
stable cutoff values, Figure 14 compared the cutoff value calculated from 107  or 108 
randomly selected candidate gene sets for gene set sizes 3 to 7 based on the TCGA ovarian 
cancer dataset. The cutoff value determined using 107 gene sets was stable. Increasing the 
number to 108 did not lead to any notable change. As the computational time of calculating 





Figure 14. TG cutoff value estimation. For each size of candidate gene sets, the cutoff value 
of TG for controling FDR < 0.05 was estimated by sampling 107 (red square) or 108 (blue 
diamond) candidate gene sets. 
 
3.7.4 Whole genome data analysis 
We applied our method to TCGA glioblastoma (Brennan et al., 2013), squamous 
cell lung cancer (Cancer Genome Atlas Research, 2012), ovarian cancer (Cancer Genome 
Atlas Research, 2011), pan-cancer (Cancer Genome Atlas Research et al., 2013; Kandoth 
et al., 2013), and breast cancer (Cancer Genome Atlas, 2012) studies. All the data were 
downloaded from Synapse (syn1729383) (Kandoth et al., 2013). For each dataset, we 
limited our analysis to non-synonymous mutations and focused on non-synonymous 
mutations and filtered out genes with no more than one mutation. The filtered datasets 
contain 3193 to 16984 genes. We applied MEScan and searched for mutual exclusive gene 
sets of size between 2 and 7. For each gene set size, 4 independent MCMC chains, each 
having 108  iterations with 5 × 105  burn-in iterations, were generated using 4 different 
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random seeds and the results were pooled together. To control for FDR, we randomly 
selected 107 gene sets of a given size to estimate the empirical null distribution of TG and 
FDR. We chose the cutoff value of TG score such that FDR <  0.05 and called gene sets 
with TG scores higher than the cutoff value as significant mutually exclusive gene sets. 
Finally, high-confidence mutually exclusive sets were determined by investigating the 
consensus of mutually exclusive gene sets across different sizes. Below, we focused on 
some of these high-confidence mutually exclusive sets and explored their biological 
interpretations. The selection of these interesting cases was based on the biological 
importance and relevance of these gene mutations as well as the clinically actionable 





Figure 15. High-confidence mutually exclusive gene sets identified from real data analysis. 
MEScan was applied to identify high-confidence mutually exclusive gene sets based on A) 
TCGA glioblastoma (n=290); B) TCGA lung squamous cell carcinoma (n=174); C) TCGA 
ovarian cancer (n=314); and D) TCGA pan-cancer datasets (n=3205). One selected high-
confidence mutually exclusive gene set from each dataset was presented in this figure.  
 
3.7.4.1 Glioblastoma 
We identified a high-confidence mutually exclusive set with IDH1, EGFR, PTEN 
and PIK3CA (Figure 15A). Aberrant PI3K/Akt signaling is frequently observed in cancers 
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including glioma, which often is achieved by loss of the PI3K inhibitor PTEN (phosphatase 
and tensin homolog) or gain-of-function mutations of EGFR (X. Li et al., 2016; H. Xu et 
al., 2017) or PI3KCA (Carracedo & Pandolfi, 2008). IDH1 is a NADP-dependent enzyme 
that catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG) in the 
TCA cycle. IDH mutations are frequently present in gliomas and result in a gain of enzyme 
function of NADPH-dependent reduction of α-ketoglutarate to 2-hydroxyglutarate that 
promotes tumorigenesis (Philip et al., 2018). Mutant IDH1 activates mTOR signaling 
downstream of the PI3K/AKT/TSC1/2 pathway by inhibiting KDM4A, an α -KG-
dependent histone demethylase (Carbonneau et al., 2016). Thus, in glioblastoma, we have 
identified three regulators of PI3K/AKT/mTOR signaling.  
3.7.4.2 Squamous cell lung cancer 
A high-confidence mutually exclusive set we identified consists of three genes, 
kelch-like ECH-associated protein 1 (KEAP1), phosphatase and tensin homolog (PTEN) 
and nuclear factor erythroid-2-related factor 2 (NFE2L2/NRF2), see Figure 15B. NRF2 is 
a transcription factor and critical regulator of response to oxidative stress. KEAP1 is a 
negative regulator of NRF2, and in response to oxidative stress, NRF2 is released from 
KEAP1 where it travels to the nucleus and activates transcription of target genes, that are 
generally anti-oxidants. When KEAP1 is mutated, NRF2 accumulates (X. Chen, Zhang, 
Zhang, & Gao, 2019). Constitutive activation of NRF2, either through mutations in NRF2 
itself or the regulatory partner KEAP1, is recognized to increase tumorigenesis as well as 
drive resistance to chemotherapies. In addition, many lung cancers have constitutive NRF2 
activation in the absence of NRF2 and KEAP1 mutations (Kerins & Ooi, 2018). PTEN has 
recently emerged as a negative regulator of NRF2, and loss of PTEN is associated with 
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constitutive activation of NRF2 (Best et al., 2018). Therefore, our analysis has identified 
two regulators of a final common transcription factor, strongly implicated in tumorigenesis 
and resistance to chemotherapy.  
3.7.4.3 Ovarian cancer 
Breast cancer gene 1 (BRCA1), neurofibromatosis type (NF1) and cyclin-
dependent kinase (CDK) 12 was identified as a high probability mutually exclusive gene 
set in ovarian cancer (Figure 15C). CDK12 is transcriptional regulator of DNA damage 
response (DDR) genes including those involved in the homologous recombination (HR) 
like BRCA1 (Joshi, Sutor, Huntoon, & Karnitz, 2014; Paculov\'a & Kohoutek, 2017), via 
phosphorylation of the RNA polymerase II C-terminal domain. Loss of function mutations 
of CDK12 result in compromised DDR and homologous recombination, which is observed 
in ovarian cancers(Joshi et al., 2014). Neurofibromatosis is a hereditary syndrome in which 
individuals typically develop benign neurofibromas because of neurofibromin 1 (NF1) 
mutations, but are also at increased risk of breast cancer(Jeon, Kim, Lim, Choi, & Suh, 
2015). Recent work demonstrated an association between NF1 deletions and ESR1, the 
gene for the estrogen receptor (ER) expression and ER positivity (Dischinger et al., 2018). 
In breast cancer, NF1 binds to and represses ER and loss of function mutations of NF1 
activate ER transcriptional pathways (Chang et al., 2018). Like breast cancer, ovarian 
cancer is a hormone-responsive cancer with ER present in about 60–100% of ovarian 
cancers (Modugno et al., 2012). It’s likely that for ovarian cancers, there are two subtypes. 
One is driven by mutations in CDK12/BRCA signaling while the other is driven by 
mutations in NF1/ER signaling. Our gene set analysis has thus identified mechanisms of 




CDKN2A, NPM1, RPL22, SMC1A was identified as a high-confidence mutually 
exclusive gene set from TCGA pan-cancer data (Figure 15D). P53 is a well-established 
tumor suppressor in human cancer. CDKN2A encodes p14ARF, which inhibits MDM2 
and promotes p53 function such as cell cycle control, apoptosis and tumor suppression 
(Sherr, 2006). NPM1 (nucleophosmin) complexes with and stabilizes p14ARF (Sherr, 
2006). Mutated NPM1 fails to protect p14ARF from degradation and attenuates the ability 
of p14ARF to promote p53 function (Colombo et al., 2006) NPM1 also directly interacts 
with p53 and positively regulates the stability and transcriptional activity of p53 (Colombo, 
Marine, Danovi, Falini, & Pelicci, 2002). RPL22 (Ribosomal protein L22) is highly 
mutated in various human cancers. Studies have shown that RPL22 binds with and inhibits 
MDM2 E3 ligase and thus functions as a p53 positive regulator (Cao et al., 2017). Finally, 
SMC1A is a component of the cohesin complex that plays a crucial role during mitosis in 
holding sister chromatids together from DNA replication in S phase to anaphase to ensure 
proper chromosome separation. SMC1A mutations would impact cohesin functions 
(Hirano, 2006) and would theoretically result in error-prone chromosome replication and 
segregation, which may induce p53-mediated cell cycle control, although it has not been 
experimentally confirmed. The cohesin complex has been shown to bind to the 
transcription start sites of p53 and mdm2, and the knockdown of Rad21 (a cohesin 
component) increased their transcription (Rhodes et al., 2010). It is possible that SMC1A 
mutations would enhance p53 and mdm2 transcription. Thus pan-cancer mutations in 
CDKN2A, NPM1, RPL22, and SMC1A can be functionally connected through the 




3.7.5 Real world validation and comparison 
We used four real data sets to validate our method from different aspects. We also 
tried to compare our method to existing ones when possible. Note that we attempted to try 
existing methods on the whole-genome real data examples presented in the last subsection. 
However, all attempts with those methods failed to finish.  Dendrix ran out of computer 
memory (i.e > 64 GB of RAM).  MEGSA, CoMEt and WEXT did not finish after using 
over 6 days of CPU time.  Therefore, we compared our methods to others using a smaller 
scale real data example presented in the first validation study of this subsection, where 
some of the existing methods were able to generate results. 
Our first validation study considered the pan-cancer data on 299 driver genes from 
TCGA MC3 (Li Ding et al., 2018) to assess whether MEScan as well as other methods can 
identify the mutually exclusive patterns reported in the paper. Two sets of analyses were 
performed. The first set of analyses focused on examining all candidate gene sets of size 2.  
Ding et.al (Li Ding et al., 2018) reported 8 mutually exclusive gene sets  based on the exact 
Mantel-Haenszel test. MEScan was able to identify all those 8 gene sets as significantly 
mutually exclusive. In contrast, WExT was able to identify 7, CoMEt was able to identify 
1, Dendrix was unable to identify any of those gene sets, and MEGSA was unable to 
complete the analysis with 6 days of CPU time. The second set of analyses focused on 
examining candidate gene sets of size >2.  Ding et.al (Li Ding et al., 2018) reported 4 such 
gene sets.  MEScan was able to identify all of them as significantly mutually exclusive. In 
contrast, Dendrix was unable to identify any of those gene sets, and other methods were 
unable to complete the analysis with 6 days of CPU time. Our second validation study 
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considered the set of BRAF and NRAS, whose mutations are known to be mutually 
exclusive in melanoma (Akbani et al., 2015). We applied each method to TCGA melanoma 
data (Akbani et al., 2015) (n=253). We focused on all gene sets of size 2 and investigated 
whether a method was able to identify the gene set of BRAF and NRAS. MEScan gave a 
𝑇𝑇𝐺𝐺 score of 125.6 for the set of BRAF and NRAS, which is highly significant. In contrast, 
other methods were unable to finish after using over 6 days of CPU time.  Our third 
validation study used an independent large-scale cohort, PCAWG (Consortium, 2020), to 
validate the our findings from TCGA pan-cancer analysis. The PCAWG cohort contains 
1810 cancer patients after excluding overlapped patients between PCAWG and TCGA. 
After filtering out a few genes with no observed mutations in the PCAWG cohort, we 
examined a total of 149 high-confident mutually exclusive gene sets we identified from the 
TCGA pan-cancer cohort. 95% of those gene set were also significantly mutually exclusive 
in the PCAWG cohort. Our fourth validation study used an independent cohort of 2,433 
primary breast tumors (Pereira et al., 2016) to validate our findings from TCGA breast 
cancer analysis. Because the validation cohort sequenced a panel of 173 genes, we focused 
our analysis on high-confidence gene sets consisting of those genes. 84% of those gene 
sets remained significant in the validation cohort. These four validation studies suggested 
that MEScan was able to identify known mutually exclusive patterns and provide 
reproducible results. 
3.8 Discussion 
We have introduced a statistical framework, MEScan, for accurate and efficient 
genome-wide de novo discovery of mutually exclusive gene sets. Our framework uses a 
simple yet powerful statistical test for identifying mutually exclusive gene sets. The test 
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allows adjustment of background mutation rate, mitigates the impact of highly mutated 
genes, and is very fast to calculate. Coupled with this test is an MCMC algorithm to 
efficiently screen candidate gene sets at the genomic scale. MEScan is able to search 
through thousands of candidate genes without restricting to known cancer drivers or genes 
with high mutation rates. To reduce false positives, we use an FDR control procedure to 
identify significant gene sets and a summarization method to further select high-confidence 
mutually exclusive gene sets. Although our method focuses on detecting mutual exclusive 
patterns, it could potentially be extended to detect other important mutational patterns, such 
as co-occurrence patterns (Avivar-Valderas et al., 2018; Li Ding et al., 2018; Thomas et 
al., 2007), but the formula needs to be tweaked towards quantifying those specific patterns.  
Another important extension of our method is to include somatic copy number variations 
in the analysis. 
We noticed that mutual exclusivity could originate from different mechanisms. The 
focus of most current research is on mutations of genes from the same biological pathway. 
However, gene mutations specific to different cancer subtypes could also form a mutually 
exclusive pattern. For example, from TCGA ovarian cancer data, we identified a high-
confidence mutually exclusive gene set of BRCA1, NF1 and CDK12, which is likely to 
contain two different subtypes of ovarian cancer driven by CDK12/BRCA1 signaling and 
NF1/ER signaling, respectively. Therefore, a potential new use of mutual exclusivity 
analysis might be to identify cancer subtypes and subtype-specific gene mutations. Further 
research in this area will be of great interest. Furthermore, mutually incompatible mutations 




One limitation of MEScan is that it does not account for intratumoral heterogeneity. 
Mutations identified using whole-exome bulk sequencing usually come from a mixture of 
multiple subclones within a tumor(McGranahan & Swanton, 2017). Delineating the 
intratumor heterogeneity (Schwartz & Sch\"a, 2017) could provide a cleaner signal to 
improve mutual exclusivity analysis. Furthermore, recent advances in single-cell 
sequencing technologies (Zhang et al., 2019) hold the promise of revealing intratumor 
heterogeneity at a much higher resolution. With the accumulation of such data, performing 





CHAPTER 4. FastCount: A Fast Gene Count Software for Single Cell and Bulk RNA-
seq Data 
4.1 Introduction 
4.1.1 Bulk RNA-seq gene quantification 
RNA sequencing (RNA-seq) has become one of the most commonly used 
techniques for transcriptome profiling in a wide spectrum of biomedical and biological 
research. Analyzing RNA-seq reads to quantify expression at each gene locus is the first 
step towards any downstream biological interpretation. 
There are two popular gene expression estimation methods: gene count and 
transcript abundance. Gene count is essentially the total number of reads sequenced within 
a gene. Many popular statistical differential expression methods such as DESeq2 (Love et 
al., 2014) and edgeR (Robinson et al., 2010) take gene count as input. They model it as 
negative binomial distribution to deal with biological variability and overdispersion and 
determines differential expression using exact tests (Seyednasrollah et al., 2015). Several 
tools such as featureCounts (Liao et al., 2014) and HTSeq (Anders et al., 2015) are used to 
obtain the gene counts. These softwares require several preprocessing steps on the raw 
RNA-seq reads before performing read counts: 1) generally, a read trimming step is 
necessary to remove adapter sequences and low-quality bases from the FASTQ files 
(Bolger et al., 2014; Martin, 2011a). This improves the mappability of the reads during the 
downstream alignment step. The quality trimming criteria, such as minimum base quality 
score or a number of bases to be trimmed on start or end of each read, are selected 
empirically by the users. The processing time ranges from 10 ~ 60 minutes depending on 
the different algorithms. 2) next, trimmed reads are aligned to either the reference genome 
or the reference transcriptome using RNA-seq mappers, such as Bowtie2 (Langdon) and 
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STAR (Bohnert, Vivas, & Jansen), to generate BAM files. 3) Aligned reads in the BAM 
files are assigned to genes based on the genomic locations provided in the Gene Annotation 
File (GTF) for gene-level read counts. Although there are some efficient algorithms 
available, such as featureCounts to summarize read counts from the BAM file, read 
alignment is computationally intensive, requiring large memory and CPU time. 
Alternatively, read counts can be derived from transcript abundance using tools specially 
designed for transcript-level abundance estimation. Transcript expression is first quantified 
using tools like RSEM (B. Li & Dewey, 2011), Kallisto (Bray, Pimentel, Melsted, & 
Pachter, 2016) and Salmon (Patro, Duggal, Love, Irizarry, & Kingsford, 2017), followed 
by additional gene-level expression estimation. RSEM, first performs read mapping using 
the read aligner mentioned above and uses the Expectation Maximization (EM) algorithm 
to estimate abundances at the isoform and gene levels. However, RSEM does not scale 
well due to the high computational requirements. Kallisto and Salmon on the other hand, 
are alignment-free algorithms where reads are not directly aligned but rather assigned to 
the most likely transcript that generated them using 𝑘𝑘-mers. Those methods avoid the time-
consuming read alignment steps and report expression abundance (Teng et al., 2016) on 
transcript levels. Gene-level read counts are estimated using the transcript-level expression 
by customized scripts or third-party tools to correct gene length changes from differential 
isoform usage {Soneson, 2015 #162}. Therefore, current methods suffer from the 
following problems: the accuracy of alignment-based methods depends heavily on the 
performance of the aligners (Baruzzo et al., 2017) and the scalability is poor in large scale 
study; assigning reads to transcripts is more challenging than to gene due to the repetitive 
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sequences among the transcripts (Teng et al., 2016); and no efficient tools that are specially 
designed to correctly derive gene-level abundance (Soneson et al., 2015). 
4.1.2 Single-cell RNA-seq gene quantification 
Bulk RNA-seq quantifies the overall transcriptome changes in a collection of cells 
with the assumption that cells are homogenous within the sample. However, more 
evidences have shown that (Michael S. Lawrence et al., 2013) (Burrell et al., 2013) tumor 
cells have highly distinct cell types with each types of cells at different cell states. Bulk 
RNA-seq averages out the gene expression profile leading to the cell-to-cell variability 
information unusable (Suva & Tirosh, 2019). The advent of single cell RNA-seq (Klein et 
al., 2015; Macosko et al., 2015; Zheng et al., 2017) enables scientists to characterize the 
transcriptomic response of cancer cells under different treatment, understand intratumor 
expression heterogeneity and infer pseudo-time ordering in cancer development. The 
increasingly usage of scRNA-seq in the cancer research community necessitates the 
development of efficient and accurate algorithm to handle the large amount of scRNA-seq 
data.  
The goal of scRNA-seq is to generate abundance × cell expression matrix that can 
be used for the downstream analyses. Similar to the bulk RNA-seq, the first step in 
analyzing scRNA-seq data is to assign reads to the reference transcriptome for quantifying 
gene expression level in each cell. In scRNA-seq , gene counts-based quantification which 
is the popular approach in bulk RNA-seq analysis (Conesa et al., 2016; Soneson et al., 
2015), is largely biased due to cDNA amplification step in the library preparation (Wang 
& Navin, 2015) leading to distorted estimation of single cells expression level. Recent 
scRNA-seq protocols (Klein et al., 2015; Macosko et al., 2015; Zheng et al., 2017) have 
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employed the unique molecular identifiers (UMIs) technique to label the original RNAs 
before the amplification step to mitigate the bias (W. Chen et al., 2018). Instead of using 
gene counts, many published statistical methods are focusing on UMI-based count matrix, 
which is the total number of UMIs associated with each gene, for a more accurate single 
cell characterization (Butler, Hoffman, Smibert, Papalexi, & Satija, 2018; W. Chen et al., 
2018). Several tools have been developed by reusing the bulk RNA-seq quantification 
methods and taking into account of the UMIs and cell barcodes information incorporated 
in the scRNA-seq protocols. Similar to bulk RNA-seq, scRNA-seq involves mapping read 
to the reference genome and assign mapped reads to gene features. 
The first challenge in scRNA-seq analysis is the amount of data that need to be 
processed. A single cell experiment generates 106 ~ 1010  reads for 103 ~ 106  cells 
(Svensson, Vento-Tormo, & Teichmann, 2018). Current methods for scRNA-seq analysis 
are mainly based on existing bulk RNA-seq tools for read mapping and assignment, with 
extended functions for UMI and cell barcode processing. Cell Ranger (Zheng et al., 2017), 
a toolkit developed by the commercialized scRNA-seq company 10X Genomics, is the 
gold standard to analyzed data generated by 10X Genomics Chromium library. It takes the 
paired-end FASTQs as input, extracts UMIs and cell barcodes for Read1 and aligns Read2 
to the reference genome using STAR (Bohnert et al.) aligner. Customized python scripts 
are provided for UMI/cell barcode correction, UMI deduplication, and UMI counting. Cell 
Ranger only counts reads that are confidently mapped to the exonic regions with valid 
UMIs and cell barcodes. zUMIs (Parekh, Ziegenhain, Vieth, Enard, & Hellmann, 2018) 
first filters reads with low-quality cell barcodes and UMIs and then mapped the rest of the 
reads to the genome using STAR (Bohnert et al.) (default setting) or other user-defined 
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mappers. It uses featureCounts (Liao et al., 2014) to summarize reads mapped to both exon 
and introns and then output the count table with UMI and cell barcode information to R to 
summarize read count. UMI-tools (Smith, Heger, & Sudbery, 2017) uses BWA to map 
reads to the reference transcriptome and only counts exonic reads. However, as read 
mapping is computationally heavy, the alignment-based methods do not scale well with the 
large number of cells that may be predicted. For example, Cell Ranger takes 31 hours to 
process 784M reads in the 8K PMBCs including around 8,000 cells.   
Another challenge in scRNA-seq data analysis is the scRNA-seq specific bias 
including 5’- or 3’- end read bias and low sequencing coverage in many of the droplet-
based or well-based protocols. During the library preparation, full-length mRNA sequences 
are processed for enzymatic fragmentation. It produces transcript fragments with different 
sizes. However, in the process of PCR amplification, the primers only recognize fragments 
that contains the oligo sequences added with primer sequences for sequencing. So only the 
5’ or 3’ portion of the transcript is retained after mRNA fragmentation (Klein et al., 2015; 
Macosko et al., 2015; Zheng et al., 2017). The alignment-free methods rely heavily on 
transcript coverage information to infer the likelihood of the transcripts of origin for each 
read (Bray et al., 2016) (Patro et al., 2017). The resulting library will only produce reads 
that are mapped to the first or the last exon of the gene, leading to biased gene body 
coverage (Ma et al., 2019). For transcripts differ primarily on the 5’ or 3’ end, accurately 
determination the transcripts of origin is difficult. Additionally, average read coverage 
from existing scRNA-seq protocols is low, around 50, 000 reads per cell. The low 
sequencing depth per cell results in reduced sensitivity for resolving transcript-level 
conflicts. Therefore, the 5’/3’-end read bias as well as the low read coverage in scRNA-
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seq make transcript-level quantification even harder due to the reduced information to infer 
the transcripts of origin in the alignment-free algorithms.  Recently benchmarking study 
has shown that alignment-free algorithms report method-specific artifacts and variances in 
the number of cells and genes detected. For example, Kallisto detects highly expressed 
genes in the Vmn and Olfr families in several of the 10X Genomics datasets, where such 
genes are known to be not expressed in the tissues.  
The third challenge in scRNA-seq analysis is to appropriately handle scRNA-seq 
specific information in the UMI and cell barcode sequences. Due to the small amount of 
RNA within each cell, a PCR amplification step is necessary to produce enough cDNA for 
the sequencing step.  The amplification bias can be corrected computationally in the 
downstream analysis using the UMI sequences. If reads with the same UMI sequences from 
the same cell are mapped to the same transcript sequence, we can conclude that they are 
technical duplicates from PCR amplification and should be collapsed. However, 
sequencing errors in the UMIs result in artefactual UMIs inflating the UMI counts (Smith 
et al., 2017). Existing methods include UMI correction step to identify multiple similar 
UMI sequences and treat them as instances of the same UMI. Cell Ranger, zUMIs and 
scPipe (Tian et al., 2018) uses a greedy algorithm comparing each UMI sequence to 
identify UMIs within certain hamming distance and collapse them to the higher count UMI. 
UMI-tools links UMIs by a single edit distance and aims to reduce the UMI network into 
a representative UMI. Salmon constructs a UMI graph to find a minimal set of transcripts 
for UMI deduplication (Srivastava, Malik, Smith, Sudbery, & Patro, 2019). Kallisto, on 
the other hand, does not perform UMI correction, and uses a naïve method to collapse reads 
that contain the same UMI. The sequencing process also introduces errors in cell barcodes. 
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Therefore, the correction of errors in cell barcodes is important in cell identification. Cell 
Ranger, zUMIs and Kallisto first compares the sequenced barcodes to a whitelist which 
contains the pre-defined barcodes in the library preparation kit. If a cell barcode is not in 
the whitelist but is 1-hamming distance away from a barcode in the whitelist, it will be 
corrected to the corresponding barcode from the whitelist. Salmon generates a putative 
whitelist by analyzing the cumulative distribution of barcode frequencies. UMI-tools only 
selects cell barcodes in the given whitelist. The various combinations of different read 
mappers, criteria of read assignments and UMI+cell barcode handling have big impact on 
the gene expression quantification rendering inconsistency in expression differences 
detection, cell clustering and trajectory analysis (Simonsen et al., 2018; Tian et al., 2019). 
4.2 FastCount algorithm 
Despite the existence of large number of tools for bulk and scRNA-seq gene 
quantification, these methods face the following challenges: existing methods do not scale 
well for large data set especially in the application for the single cell experiment where 
millions of reads are sequenced for a single sample; the alignment-free methods are 
sensitive to the sequencing read depth and gene body coverage; and the alignment-free 
methods provide at least 4 times speed improvement but with the tradeoff for accuracy.  
Therefore, we present FastCount, an alignment-free approach to directly assign 
read to gene-level features. FastCount skips the computationally intensive read mapping 
step and assign reads directly to genes of origin based on the gene-specific 𝑘𝑘 -mers 
information. We hypothesize that using gene-specific 𝑘𝑘-mers information simplifies the 
gene-level read assignment problem than transcript-specific information and improves the 
performance in terms of speed and accuracy.  
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FastCount is capable of alignment-free supports alignment-free UMI count 
summarization for scRNA-seq data and gene count quantification for bulk RNA-seq data 
leveraging gene-specific k-mers. Different from the alignment-based algorithms that 
include a computationally intensive read mapping step, FastCount assigns an RNA-seq 
read directly to the potential gene based on its k-mer origin information. FastCount uses a 
novel data structure, GeneOthello, to assign reads to the corresponding gene identifiers 
sharing approximately the same set of k-mers. It conducts read count in a gene without 
necessitating detailed read alignment information. FastCount is implemented to handle 
UMI and cell barcode information specific to scRNA-seq data, allowing a speedy 
assessment of scRNA-seq cell distribution using raw sequencing reads. We demonstrate 
through experiment that FastCount scRNA-seq application using 10X Genomics data and 
compare the performance to 10X Genomics' toolkit, Cell Ranger. FastCount is over an 
order of magnitude faster than Cell Ranger with very competitive accuracy. We also 
demonstrate that FastCount is about two orders of magnitude faster than the gold standard 
bulk RNA-seq tool, RSEM while achieves competitive accuracy. 
4.2.1 Gene 𝑘𝑘-mers signatures 
The term "gene count" typically refers to the number of reads sequenced in each 
gene within a given RNA-seq sample. Calculating gene count requires assigning each read 
to the gene it is sequenced from. Unlike read alignment, read assignment does not require 
high resolution base-by-base continuous matching between the read sequence and genomic 
reference. Instead, read assignment can be simplified to the identification of the gene that 
best matches the set of k-mers present in the read. When k = 21, the majority of k-mers 
(93.9% in GRCh38) are unique to the genes carrying them (Figure 16). Therefore, the gene-
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specific k-mers may serve as signatures for read classification problem. The rest of the k-
mers (6.1% in GRCh38) appear in more than one gene. FastCount leverages this property 
and turns gene count into a read assignment problem. 
The first step of FastCount method is to establish a mapping between k-mers and 
genes. The k-mers in RNA-seq are expected to be from mRNA transcriptome although 
these can be expanded to include other RNA species as well. Therefore, we extract all the 
k-mers present in the transcript sequences of each gene. These k-mers 𝑆𝑆 are divided into 
two categories: gene-specific k-mers and gene-clique k-mers. Each of the gene-specific k-
mers can uniquely identify one gene. Each of k-mers in a gene clique set is not unique to a 
gene and instead, is shared by a set of genes, which we refer to as a gene clique. Those k-
mers are often a result of repetitive sequences but provide useful information on handling 
reads that map ambiguously to multiple genes. Thus, we would like to establish a mapping 
between the set of transcriptome k-mers and their associated gene features. a). Formally, 
let 𝐺𝐺 be genes corresponding to gene-specific k-mers and 𝐶𝐶 be the set of gene cliques.  Let 
𝐹𝐹 be a feature set containing genes in 𝐺𝐺 and gene cliques in 𝐶𝐶, where 𝐹𝐹 =  𝐺𝐺 ∪  𝐶𝐶 and 
𝐺𝐺 ∩  𝐶𝐶 =  0  Thus, there exists a many-to-one mapping between 𝑆𝑆 ⟶  𝐹𝐹 , such that 




Figure 16. Cumulative 𝑘𝑘 -mer percentage at different 𝑘𝑘 -mer occurrence from Human 
reference genome GRCh38.  
4.2.2 GeneOthello 𝑘𝑘-mers index 
The efficiency of gene count procedure relies on how fast one can quickly map a 
read to a gene. In our case, it is translated to how fast we can map a k-mer to a gene. To 
this end, we have adopted a hashing classifier, called Othello (Yu, Belazzougui, Qian, & 
Zhang, 2018), to facilitate the mapping between k-mers and the features 𝑆𝑆. Othello is a 
minimal perfect hashing algorithm (MPH) that provides key-to-value query in constant 
time. The othello algorithm has demonstrated great scalability in both memory and query 
speed in several Bioinformatics applications (Liu et al., 2018; Yu, Liu, et al., 2018). 
We build an index, named GeneOthello, in order to store the many-to-one mapping 
between the aforementioned transcriptome k-mers and gene features. We encode gene 
features 𝐹𝐹  as a set of l-bit integers 𝑉𝑉 = {0, 1 , 2, … , |G|, |G| + 1, |G| + 2, … , |G| + |C|}, 
where 0 is specially allocated for k-mers with occurrence > n and 𝑙𝑙 =  ⌈𝑙𝑙𝑙𝑙𝑔𝑔_2(|𝐹𝐹| + 1)⌉. 
GeneOthello O(S, V) maps the predefined set of k-mers S to the gene features in V. Let  T ∶
 S → V be the function that maps k-mers to the gene features in V, where T(k) indicates the 
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feature of a k-mer s ∈ S. GeneOthello maintains a query function τ: U → I that maps the 
universal set of k-mers, U (i.e., U = θk, θ = {A, G, C, T}) to the set of all l-bit integers, I =
{0,1, … , 2l − 1}. Therefore, S ⊂ U and V ⊂ I. GeneOthello has the following properties: 
1) given a k-mer s ∈ S, a GeneOthello querying τ(s) guarantees returning the correct gene 
feature id v; 2) for any alien k-mers, s′ ∉ S , GeneOthello has a higher probability to assign 
s' to a dummy feature τ(s′) ∈ I − V than a false positive feature 𝜏𝜏(𝑠𝑠′)  ∈  V (Yu, Liu, et al., 
2018). 
The GeneOthello structure includes a pair of hash function ⟨ha, hb⟩ and two arrays 
of l-bit integers A and B. The hash functions and the content of the integer arrays are 
precomputed during GeneOthello construction. The hash functions provide the mapping 
between the universal k-mer set and the corresponding index location in A and B, that is 
ha: U → {0,1, … , ma − 1}  and  hb: U → {0,1, … , mb − 1} . A query of a k-mer s on 
GeneOthello will first yield indices ha(s)  and hb(s) . The feature τ(s)  of k-mer s is 
computed by the integer values at A[ha(s)] and B[hb(s)] as τ(s) = A[ha(s)]⨁B[hb(s)]. 
The procedure only accesses two memory locations in A and B and a bitwise XOR 





Figure 17 A toy example illustrating FastCount algorithm. The construction of 
GeneOthello index from the reference gene sequences. In this example, k-mers (k = 3) in 
the reference set are extracted from each reference transcript. Their occurrences within 
genes are tabulated and are categorized into gene signatures and cliques (Top). A 
GeneOthello index is constructed to store the many to one mapping between the k-mers 
and the gene feature indices (Bottom).  
4.2.3 Read assignment to genes  
One of the key steps in bulk and single cell RNA-seq analysis is to accurately assign 
read to the correct gene feature. To do this, FastCount first decomposes read into 
consecutive k-mers (Figure 18 Read assignment procedure.  k-mers in a read are extracted 
and queried against GeneOthello to obtain their gene features. Continuous k-mers with the 
same gene feature are clustered into feature windows. The gene assignment of a read is 
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determined by the gene that dominates the longest feature window.) and each k-mer is 
queried against the GeneOthello index to retrieve its gene feature. Ideally, the read 
assignment is straightforward when all k-mers pointing to the same gene. However, this 
process is often complicated by the presence of alien k-mers that are absent from the 
reference transcriptome. Alien k-mers can be a result of system artifacts during the RNA-
seq library preparation and sequencing, contamination or novel transcript isoforms (Levy 
et al., 2007; Taub, Corrada Bravo, & Irizarry, 2010). When querying on alien k-mers, 
majority of them can be easily detected using the dummy features returned by GeneOthello. 
But in the cases that an alien k-mer is falsely allocated to a reference gene feature, failure 




Figure 18 Read assignment procedure.  k-mers in a read are extracted and queried against 
GeneOthello to obtain their gene features. Continuous k-mers with the same gene feature 
are clustered into feature windows. The gene assignment of a read is determined by the 
gene that dominates the longest feature window. 
FastCount tackles the challenge of alien k-mers using the following strategies: 1) 
when constructing GeneOthello index, we intentionally expand the size of I such that many 
alien k-mers are categorized into a group that is not overlapping with any valid 
transcriptome features I - V. Given the predefined V, we can increase the probability of an 




(Liu et al., 2018). 2) in the case that an alien k-mer is falsely assigned to the existing gene 
features, we require the presence of at least two consecutive k-mers returning the same 
gene feature to be considered as a feature segment for gene assignment. As the indices 
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queried by alien k-mers are random, the chance of seeing the same gene assignment from 
the two different alien k-mers is very low (Liu et al., 2018). 
FastCount performs read assignment with the following procedure: 1) it iterates 
through each k-mer along the read to retrieve its gene feature by querying against the 
GeneOthello index. With the presence of alien k-mers, gene features along the reads may 
be divided into section. We merge continuous gene features into feature segments and 
reject the dummy features from alien k-mers. Each feature segment is weighted by the wj =
dj2, where dj is the number of k-mers in the feature segment j, to take into account of the k-
mer spatial information on the read. 2) We filter feature segments with length < 2 from 
feature assignment to remove the possible alien k-mers query falsely return to the known 
features. 3) Gene segments are then ranked by the weights to identify the most dominant 
feature. 4) The rest of the feature segments are compared to the dominant feature. If there 
are no consensus gene feature among the segments, the read is removed from the 
assignment; if they all indicate a single consensus gene, the read is assigned to the gene 
feature; if they indicate to a set of genes, the case of multi-mapping read, we will not 
include this read for feature assignment. 
4.2.4 FastCount scRNA-seq implementation 
In scRNA-seq analysis, another key step is to appropriately handle the single-cell 
specific information in the cell barcode and UMI sequence. FastCount accepts sequencing 
FASTQ files that are expected to contain cell barcode and UMI information in one of the 
read files and the gene identity file in another. For example, a typical read 10X Genomics 
Chromium data is in the form of read pairs, read1 and read2 (Figure 19 Individual barcode 
identification and gene assignment for a paired-end read.). Read1 is the cell barcode 
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sequence that is used to tag the cell origin of the cDNA followed by the UMI sequence 
which labels the cDNA molecule. Read2 is the sequenced nucleotide bases from the cDNA 
segment used to determine the gene identity. FastCount algorithm integrates read pre-
filtering, read assignment, UMI correction and UMI counting steps. 
 
Figure 19 Individual barcode identification and gene assignment for a paired-end read.  
FastCount first removes read pairs with invalid CELL BARCODE or UMI sequences using 
read1. If read1 corresponds to valid CELL BARCODE and UMI barcodes, it proceeds to 
assign read2 to gene features using FastCount read assignment algorithm. 
FastCount first filters the low-quality cell barcode and UMI sequences. Due to 
potential sequencing and amplification errors in the cell barcode and UMI sequences, the 
number of detected cells and UMI counts are usually inflated. FastCount parses the cell 
barcode and UMI from the read1 and looking for any "N" bases. Read pairs with 'N's in 
either cell barcode or UMI will be skipped for the read assignment step. Cell 
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barcode+UMIs pass this filter will be further compared against the cell barcode whitelist 
which is the full list of all known cell barcode sequences that are available for cell tagging 
during the library preparation. Cell barcodes that more than 1-hamming distance apart from 
the whitelist are considered invalid. Otherwise, the reads with valid cell barcode+UMI 
sequences are assigned to its potential gene features based on its k-mers information using 




Figure 20 Cell-level feature summarization.  Our method iterates through all the read pairs 
for gene-level assignment and keeps track of the number of reads assigned to each gene 
feature for individual cells using a CELL BARCODE+UMI counts matrix. It then corrects 
UMIs based on the UMI counts and UMI sequence differences for each gene feature. The 
final feature-barcode matrix summarizes the number of unique UMIs for each gene feature 
in each cell. 
FastCount keeps tracking the association between the UMIs and gene features for 
each individual cell and stores the UMI counts in a cell barcode+UMI counts matrix. After 
iterating through all the reads for the feature assignment, FastCount will try to further 
mitigate errors in UMIs using the cell barcode+UMI counts information (Figure 20 Cell-
level feature summarization.  Our method iterates through all the read pairs for gene-level 
assignment and keeps track of the number of reads assigned to each gene feature for 
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individual cells using a CELL BARCODE+UMI counts matrix. It then corrects UMIs 
based on the UMI counts and UMI sequence differences for each gene feature. The final 
feature-barcode matrix summarizes the number of unique UMIs for each gene feature in 
each cell.). The UMI correction is performed per cell per gene feature. FastCount compares 
one UMI against the rest of UMIs under the same gene feature within each cell looking for 
the ones that are 1-hamming distance apart. An UMI with lower count is corrected towards 
the higher count UMI. The UMI corrected counts matrix then undergoes UMI 
deduplication to group duplicate UMIs and collapse them into a single consensus one. 
Finally, FastCount counts the number of unique UMIs for each gene-level feature in each 
individual cell and reports the feature-barcode matrix in the Market Exchange Format for 
downstream analysis. 
4.3 Experimental results  
We assess the performance of FastCount on bulk RNA-seq and scRNA-seq data 
analysis separately. In order to benchmark its performance on bulk RNA-seq data, we 
generate a set of simulated data and compare the gene count reported by FastCount to the 
ground truth. For scRNA-seq, datasets published by 10X Genomics are selected as 
reference sets. The feature-barcode matrix quantified by the standard 10X data analysis 
pipeline, CellRanger, is used as the ground truth to evaluate the accuracy measurement.  
4.3.1 Bulk RNA-seq simulation datasets 
We benchmark the performance of FastCount on bulk RNA-seq using simulated 
data generated by rsem-simulate-reads program from RSEM (B. Li & Dewey, 2011). The 
parameterization of the dataset is learned from real data sets following the procedure used 
in Kallisto(Bray et al., 2016). Specifically, rsem-calculate-expression was run on 
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NA12716_7 from the GEUVADIS RNA-seq data to learn the model parameters from the 
real data. We simulated 20 different data sets with 30 million 75 bp paired-ends reads using 
rsem-simulate-reads. The gene-level expression estimations reported by this program for 
each simulation set are used as the true expression levels. We calculated the pearsons and 
spearmans correlation values between the estimated abundance and the ground truth. We 
further measure the accuracy using median relative difference (MRD)  (Bray et al., 2016) 
and 5% error fraction (EF) (B. Li & Dewey, 2011) statistics.  
4.3.2 scRNA-seq 10X Genomics datasets 
Due to the lack of ground truth scRNA-seq dataset, our evaluation focuses on the 
scRNA-seq data produced using the widely accepted 10X Genomics Chromium platform. 
The filtered feature-barcode matrix quantified by count function in the Cell Ranger pipeline 
is used as the reference dataset. We compare how well each tested method correlates with 
Cell Ranger's UMI counting results. We include six datasets to exam the performance of 
the different tools in terms of different species, tissue types, sequencing depth and library 
chemistry. Datasets pbmc_1k_v3 and pbmc_10k_v3 were derived from human peripheral 
blood mononuclear cells (PBMCs) and were prepared using the 10X Chromium v3 
chemistry. We also include heart_1k_v3 and heart_10k_v3 which are cells from whole 
heart of an E18 mouse. Additionally, pbmc4k and pbmc8k are chosen to evaluate the 
performance on data generated by 10X Chromium v2 chemistry. The number of cells in 
these datasets ranges from ~ 1,000 to ~ 8,000 per sample. They were processed by 10X 
Genomics using the standard Cell Ranger pipeline. The raw sequencing FASTQ files are 
analyzed by each tool using the recommended settings. The resulting feature-barcode 
matrices are compared with the reference datasets quantified by Cell Ranger count to 
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evaluate the concordance in gene- and cell-level expression as well as in the downstream 
biological inference. 
4.3.3 Comparison with other bulk RNA-seq tools 
We evaluate FastCount's performance in terms of accuracy and scalability on 
analyzing traditional bulk RNA-seq data. We compare its performance with three popularly 
used gene count pipelines: STAR (Dobin et al., 2013) in quantMode, featureCounts (Liao 
et al., 2014) (STAR aligner) and the gold standard RSEM (B. Li & Dewey, 2011) (STAR 
aligner).  
STAR was run in 1-pass mode with "quantMode" option enable to summarize the 
number of reads assigned per gene during the mapping procedure. featureCounts was run 
on the BAM file generated from STAR output and the General Transfer Format (GTF) file 
to summarize the read counts on the gene level features. RSEM was run with STAR aligner 
and the gene level expression estimates was used for the comparison. All the tools are ran 
using their default settings.  
For each of the simulated data, we quantify the gene abundances with the four tested 
methods and measure the accuracy of gene count estimates. Table 5 Accuracy of gene 
count quantification in terms of Pearson and Spearman correlation, MRD and 5% EF using 
simulated data. shows the median values of the Pearson, Spearman, MRD and 5% EF for 
each of the tested methods using the 20 simulated bulk RNA-seq data. In general, 
FastCount achieves a competitive and sometimes slightly better performance over the set 
of gene count tools in comparison. FastCount outperforms STAR 1-PASS and 
featureCount+STAR pipelines. One major reason for the lower performance in the two 
STAR related methods is likely due to that STAR and fetureCount do not handle read 
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mapped to multiple gene features. Such reads are dropped from gene counting. RSEM, on 
the other hand, uses the Expectation Maximization (EM) algorithm to estimate the 
abundance based on the uniquely aligned reads and multi-mapped reads. In FastCount, 
multi-mapped reads are allocated to genes in proportion to the gene count quantified using 
uniquely-mapped reads.  
Table 5 Accuracy of gene count quantification in terms of Pearson and Spearman 
correlation, MRD and 5% EF using simulated data.  
 
We then measure the speed and memory usage of FastCount on bulk RNA-seq. All 
the pipelines are run on a 16-core Intel Xeon E5-2670 @ 2.60 GHZ Linux server with 64 
GB of RAM using 10 threads. FastCount is approximately an order of magnitude faster 
than STAR 1-PASS and featureCounts+STAR and is about 2 orders of magnitude faster 
than RSEM+STAR (Figure 21 Speed and memory usage of FastCount and 3 other 
pipelines : RSEM+STAR, featureCounts+STAR and STAR 1-PASS mode on the 20 
simulated data sets. (a) Total runtime for processing all the 20 simulation datasets. (b) 
Median peak memory requirement.). Additionally, FastCount requires a maximum of 1.3 
GB of memory while any other pipelines requiring about 30GB memory due to the 




Figure 21 Speed and memory usage of FastCount and 3 other pipelines : RSEM+STAR, 
featureCounts+STAR and STAR 1-PASS mode on the 20 simulated data sets. (a) Total 
runtime for processing all the 20 simulation datasets. (b) Median peak memory requirement. 
 
4.3.4 Comparison with other scRNA-seq pipelines 
We assess the accuracy of FastCount in scRNA-seq quantification and compare its 
performance to Cell Ranger, Salmon-Alevin (Srivastava et al., 2019) and Kallisto (Bray et 
al., 2016). To make the evaluation comparable to Cell Ranger, we download the reference 
packages provided by 10X Genomics for human and mouse samples. We then subset the 
GENCODE (Frankish et al., 2019) transcript sequence files for either species (human 
GRCh38.p12 release 30, mouse GRCm38.p6 release M21) with the same set of transcripts 
used by CellRanger. The common transcripts are used to construct the reference indices 
for FastCount, Kallisto and Salmon-Alevin.  
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Table 6 UMI count concordance between different methods and Cell Ranger in terms of 
median Pearson, Spearman and MRD for the 6 datasets. 
  
Each of the six datasets is processed using default settings by the tested algorithms 
to generate the raw feature-barcode matrix. We then subset this matrix to keep the same 
set of features and cells reported by Cell Ranger. The filtered matrix is then compared 
against the reference Cell Ranger results.  
We first calculate the gene-level correlation of the UMI counts for each gene across 
all cells between the tested algorithms and Cell Ranger count using the pearson's 
correlation, spearman's correlation and median relative difference (MRD) statistics per cell 
(Table 6 UMI count concordance between different methods and Cell Ranger in terms of 
median Pearson, Spearman and MRD for the 6 datasets.). The results indicate that 
FastCount shows the highest degree of agreement to the reference results in all datasets 
(median pearson's correlation = 0.998, spearman's correlation = 0.973 and MRD = 0.033). 
In comparison, Alevin and Kallisto show a less degree of concordance with cell ranger 
especially with scRNA-seq from heart tissues.  
We next examine the correlation on cell-level expression in total UMI counts 
between the tested algorithms and Cell Ranger. We calculate the total mRNA abundance 
within each cell by the sum of the UMI counts for each expressed gene in a cell. The 
correspondence in the total UMI counts per cell between the tested methods and Cell 
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Ranger is presented in Figure 22 The scatter plots of the total number of UMI counts per 
cell. We see high agreements between the three alignment-free methods and Cell Ranger 
with points centered around the diagonal line in the scatter plots. FastCount has the highest 
degree of concordance in all the six tested datasets, while the total UMI counts by Alevin 
and Kallisto show larger variations from the Cell Ranger reference results. Kallisto 
consistently overestimates the total gene expression level in the cells. We also observe that 
many low-expressed cells in the two mouse heart tissue datasets (heart_1k_v3 and 
heart_10k_v3) are missing in Alevin while they are all identified by FastCount, Kallisto 
and Cell Ranger count. These findings agree with the benchmark paper reported by 
(Brüning, Tombor, Schulz, Dimmeler, & John, 2021). 
We further assess the cell-level concordance by calculating the pearson's 
correlation in the UMI count of the same cell between the tested methods and Cell Ranger. 
We plot the density of the correlation coefficient as a function of total UMI counts per cell 
in Figure 23 Pearson correlation of UMI counts within each cell as a function of total UMI 
counts per cell. Each point represents a cell and the points are colored based on the number 
of neighboring points indicating the overall distribution of the correlation. The pearson's 
correlation in the cell-level UMI counts between FastCount and Cell Ranger clustered into 
a much narrower range and most of the cells have correlation coefficiency close to 1. In 
contrast, many cells show relatively lower correlation in Alevin and Kallisto indicated by 





Figure 22 The scatter plots of the total number of UMI counts per cell  between Cell Ranger 
and each of the tested algorithms (FastCount, Salmon and Kallisto) from the six 10X 
Genomics scRNA-seq datasets. 
 
 
Figure 23 Pearson correlation of UMI counts within each cell as a function of total UMI 





Figure 24 Compatible t-SNE plots using the feature-barcode matrices generated by Cell 
Ranger, FastCount, Kallisto and Salmon for the six 10X Genomics scRNA-seq datasets. 
 
Lastly, to evaluate the the impact of the different cell gene count tools on 
downstream cell clustering analysis. We perform dimensionality reduction using t-
Distributed Stochastic Neighbor Embedding (t-SNE) for each dataset using scater package 
{McCarthy, 2017 #752}. Figure 24 Compatible t-SNE plots using the feature-barcode 
matrices shows that the t-SNE plots from Cell Ranger and FastCount are very similar 
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across all six data sets, retaining all the clustering structures and embedding shapes. In 
contrast, the distribution of clusters varies significantly using Alevins and Kallisto cell 
count results. The difference becomes more apparent when the composition of clusters is 
complex. 
4.3.5 Runtime comparison 
We benchmark the runtime used for each algorithm using the six testing datasets. 
All methods are evaluated on a 16-core Intel Xeon E5-2670 @ 2.60 GHZ Linux server 
with 64 GB of RAM using 10 threads. The result is shown in Table 7 Runtime comparison 
on 10X Genomics single cell gene expression datasets in different tools. In general, 
FastCount is at least 1.5 orders of magnitude faster than Cell Ranger count. For example, 
FastCount used only 4.1 minutes to process 1K PBMCs data set which contains around 
1000 cells and 66 million of reads, while Cell Ranger took 154.2 minutes. For 8K PBMCs 
which contains around 8000 cells and 784 million of reads, FastCount used only 46.5 
minutes, while Cell Ranger needed 31 hours. FastCount is around 3 times faster than 
Alevin except for the 2 mouse heart samples. This is because Alevin pre-filtered many 
(25.6% in 1K Heart, 26.8% in 10K Heart) cells before the read assignment and UMI 
quantification steps which largely reduced the number of reads required for processing. 
This pre-filtering step resulted in many cells missing from the final expression matrix. 









4.4  Conclusion 
In this chapter, we present FastCount, a novel alignment-free approach to quantify 
gene count in individual cells with scRNA-seq data. Comparing to the other alignment-
free algorithms, FastCount shows a higher degree of concordance with Cell Ranger's 
cellranger count in both cell-level and gene-level expression, in the meantime provides 
1.5 orders of magnitude speed improvement over Cell Ranger. 
FastCount assigns sequencing reads directly to genes using gene-specific and gene-
clique k-mers. It fully utilizes the cell barcode and UMI information in the sequencing 
reads to computationally allocate reads to the cells of origin while identifying technical 
artifacts from PCR amplification. We evaluate the accuracy of FastCount on scRNA-seq 
quantification using the results reported by Cell Ranger as the reference data sets. We 
observe that different quantification pipeline implementation influences the single cell 




The read processing step of scRNA-seq data is the first and most fundamental step 
during the scRNA-seq analysis pipeline. However, the commonly used Cell Ranger count 
often requires many hours of CPU times and extensive resources that are only available 
to computational servers. Being capable of processing 1,000 cells under 5 minutes on a 
regular laptop, Fastcount provides a lightweight but fast alternative, making it possible to 
combine cell count together with downstream analysis such as Seruat or Scanpy in one 
pipeline.   
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CHAPTER 5. Conclusion 
Cancer research is in the genomics era. Large-scale cancer genomics research has 
been focusing on comprehensive characterization of the cancer landscape using massive 
production of genomic, transcriptomic, epigenomic, and proteomic data. Bioinformatics 
methods have become one of the key components in cancer study that transform the 
sequencing reads generated by various Next Generation Sequencing assays into 
information that is interpretable by the biologist.  Accurate analysis of NGS data is a critical 
step upon which virtually all downstream interpretation process relies. Despite an active 
research field in the past decade, existing methods are still facing the challenge of high 
complexity and weakness in performance. This dissertation presents three novel 
computational methods for developing robust and reproducible NGS pipeline platform, 
efficient genome-wide driver mutation identification algorithm and alignment-free 
quantification algorithm for bulk RNA-seq and single cell RNA-seq .  
In the second chapter of the dissertation, I developed a robust, reproducible and 
scalable Bioinformatics pipeline framework that streamlines the DNA sequencing analysis 
workflow for cancer genomic mutation identification. It automates the best practice 
mutation calling pipelines to detect somatic single nucleotide polymorphisms, indels and 
copy number variation from DNA sequencing data and perform various downstream 
analyses. It integrates mutation annotation, clinically actionable therapy prediction and 
data visualization that simplifies the sequence-to-report data transformation. It has been 
applied to the real-world data that characterizes the genomic landscape of squamous cell 
lung cancer from Appalachian Kentucky using whole exome sequencing data. It is the first 
sequencing effort that provides an overview of the somatic alterations and copy-number 
111 
 
variations, explores unique mutational patterns comparing to the TCGA cohorts, and 
indicates clinically actionable assessment of mutations in this population. 
Large-scale sequencing efforts identify thousands of somatic mutations from 
cancer samples. Differentiating the driver mutations among a vast pool of passenger 
mutations is an important but challenging task in cancer research. In the third chapter, I 
developed MEScan, which is one of the first method that enables genome-scale driver 
mutations identification based on mutual exclusivity test using cancer mutation data. 
MEScan implements an efficient statistical framework to de novo screen mutual exclusive 
patterns and in the meantime taking into patient-specific and gene-specific background 
mutation rate and adjusting the heterogenous mutation frequency. It outperforms several 
existing methods based on simulation studies and is at least 2-fold of magnitudes faster 
than most of the tools. MEScan implements a Markov chain Monte Carlo (MCMC) 
algorithm to efficiently scan for mutually exclusive gene sets at the genomic scale, a false 
discovery rate (FDR) adjustment procedure to control false positives, and a summarization 
procedure to select high-confidence findings. Genome-wide screening using existing 
TCGA somatic mutation data discovers novel cancer-specific and pan-cancer mutually 
exclusive patterns.  
Recent advances in scRNA-seq technology allows cancer biologists to appreciate 
heterogeneous gene expression changes on the cellular level. scRNA-seq data processing 
using current methods is computationally challenging due to the volume of the data 
generated in a single cell experiment as well as the single cell specific information carried 
in the reads. In the fourth chapter, I designed and implemented a light-weight RNA-seq 
read classification algorithm based on gene-specific k-mers in the transcriptome. It 
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provides comparable accuracy to the current gold standard algorithm, but achieves around 
two orders of magnitude speed improvement. I further extended this read classification 
algorithm for single cell RNA-seq quantification by incorporating the cell barcode and 
UMI information. It quantifies 800 Million reads of 8,000 cells in less than 50 minutes 
which is over an order-of-magnitude faster than the classic 10X Genomics Cell Ranger (31 
hours) workflow while providing competitive accuracy in terms of UMI counts, cell 
clustering and differentially expressed genes.  
Cancer research has become increasingly data centric and relies heavily on the big 
data generated from various sequencing assays to interrogate genomic changes using multi-
Omics data. Cancer Bioinformatics research has become a key component in supporting 
the cutting-edge cancer research. Therefore, novel method development in Cancer 
Bioinformatics continues to be in high demand driven by novel biomedical applications. 
The works presented in this dissertation are expected to resolve some of the fundamental 
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